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The Patient-Centered Medical Home (PCMH) model of care is based on 
coordinated team care that provides personalized and sustainable medical interventions. 
Meanwhile, the heavy burden imposed by diabetes to the health care system is rising and 
this burden is even higher among underserved populations. Multidisciplinary team care 
has been shown to improve diabetes management. However, pharmacists’ involvement in 
PCMHs varies among settings and few studies have described their integration. This 
qualitative study describes the pharmacy services integration in PCMHs as adopted by 
Federally Qualified Health Centers (FQHC) in Austin, Texas. All four clinics in this 
study have pharmacists who are integrated in the medical team, and who provide 
pharmacy services according to a collaborative practice agreement. Since early 2013, 
three of the PCMH group clinics instituted co-visits, where the patient sees both the 
physician and the pharmacist on the same day.  
 vii 
Separate interview sessions were conducted independently with the three PCMH 
FQHCs and one usual care FQHC to describe the implementation of diabetes-related 
pharmacy services. A semi-structured interview guide was developed beforehand and the 
interviews were audio recorded. Qualitative content analysis was conducted, 
independently, by two researchers to categorize pharmacists’ responses. Discrepancies 
were resolved through discussions. 
Clinical pharmacists in the FQHCs work collaboratively with physicians and 
provide services as guided by the collaborative practice agreement. On co-visit days 
(PCMH clinics only), the pharmacists may see the patients before or after physician 
consultation. This co-visit arrangement allows for more collaboration and more efficient 
communication with physicians. Payment that recognizes value of PCMH is one principle 
of PCMH that is not fully realized in the study sites.  
In conclusion, the structure of PCMH and the integration of pharmacy services 
employed by the FQHCs incorporated the criteria of the Joint Principles of PCMH, 
namely, personal physician, physician-directed medical practice, whole person 
orientation, coordinated and/or integrated care, quality and safety, and enhanced access. 
Effective integration of pharmacist in the PCMH demonstrates that the workflow is 
established according to the needs of organization and the PCMH caters to alleviate the 
burden of primary care activities in an underserved patient population. 
 viii 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1  INTRODUCTION AND BACKGROUND 
In the United States, 80% of adults have medications as part of their treatment 
plan and about 30% of the population are taking at least 5 different drugs.1 Medication 
management is therefore important to ensure safety and efficacy of medications. 
Medication-related problems and medication errors are costly, and they account for more 
than USD 200 billion per year with continuous annual increments.2,3 Patients may receive 
their prescription and over-the-counter medications as well as supplements from different 
sources, which may lead to drug interactions and adverse events. The absence of a 
comprehensive medication list and the lack of communication between health care 
professionals can compromise safety and quality of care.4 
 
Meanwhile, the heavy burden imposed by diabetes to the health care system is 
rising worldwide and in the US.5,6 The latest data estimated that about 9.3% of the 
population in the US have diabetes and it is in the top ten leading causes of death in the 
country.7 The burden of diabetes is even higher among underserved populations, 
predominantly minorities, low-income and uninsured patients.8–10 The disparity in health 
care access and diabetes outcomes has been linked to lower education levels and cultural 
barriers. Multidisciplinary team care that provides patient-centered services have been 
shown to improve the management of diabetes for underserved patients.11–13 
 
The overall state of poor medication management and challenges in diabetes 
management with disadvantaged populations are issues that should be urgently 
addressed. Pharmacist involvement with medication management in a team-based 
approach has been recommended for these challenges and improved outcomes, such as 
decreased HbA1c, have been reported by models of care that have integrated 
pharmacists.14–16 Further, a report of Priority Areas for National Action: Transforming 
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Health Care Quality revealed that the collective expertise of a primary care team, which 
included pharmacists, is required to enhance the quality of health care.17 Additionally, 
emphasis has been placed on the need to include patients in the decision-making process 
to empower them and to promote active participation in their own medication 
management.18  
 
The patient-centered medical home (PCMH) concept corresponds to these needs 
of the health care system. The PCMH model of care is based on coordinated team care 
that provides personalized and sustainable medical interventions, as opposed to episodic 
care that can oftentimes be reactive as opposed to proactive.19,20 PCMH aims to provide 
comprehensive primary care that ultimately improves the quality and decreases the cost 
of health care services.19,21 Although the concept of PCMH has existed since 1967, there 
has been a renewed interest prompted by the Affordable Care Act (ACA), and 
Accountable Care Organizations (ACOs), both of which promote integration within 
health care teams.19,21,22 
 
In the original model of PCMHs, pharmacists were not specifically named and 
even in the most current models, pharmacists are seldom mentioned in medical home 
discussions. However, there is growing recognition of shared responsibilities among 
health care team members and justification for pharmacist involvement as members of 
PCMHs has been reported in the literature.23,24 Pharmacists’ roles include comprehensive 
medication management or the commonly interchanged term, medication therapy 
management (MTM). The provision of MTM by pharmacists is an important component 
of a successful PCMH, which is anchored in team-based care.14 Besides that, 
pharmacists’ proficiency in providing medication reconciliation, actively managing 
medication-related problems, developing individualized care plans, making interventions, 
providing referrals, and following-up to evaluate outcomes is parallel with the PCMH’s 
concept of continuity of care.14,18 
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Pharmacists’ involvement in PCMHs vary among settings and few studies have 
described their integration into these models of care. One guiding principle is that 
pharmacy services should be integrated according to the needs of the specific PCMH.25 
Published studies describing pharmacist involvement typically focus on structure (e.g., 
employment, responsibilities, workflow) and outcomes. Regarding employment, 
pharmacists can be hired by the organization directly or they can contract out their 
clinical services to provide MTM. The latter provides more flexibility for patients in 
terms of when and where they receive services.24,25 Responsibilities are typically outlined 
in collaborative practice agreements between the physician and the pharmacist. These 
agreements delegate authority to the pharmacist to provide agreed upon patient care 
services (e.g., adjustment of dosage regimens and ordering laboratory procedures).23 As 
of 2010, approximately 46 states have pharmacy collaborative practice acts.23 These state 
policies facilitate and support more pharmacist involvement in patient care activities. 
 
In addition to the structure components of employment and responsibilities, 
workflow should also be tailored to the specific institution. One aspect of workflow is the 
timing of pharmacist visits, which may occur before, during, or after the primary care 
provider visit (i.e., on the same day) or on a separate day. Another aspect of workflow is 
the criteria used to determine the need for clinical pharmacist visits. Some PCMHs may 
schedule a clinical pharmacist visit for every patient or for selected patients that meet 
specific criteria, such as physician referral only or based on specific predetermined 
criteria (e.g. HbA1c more than 9%, more than 5 chronic medications).24 The workflow 
should be agreed on to ensure effective communication among the health care team and 
the patient.25  
 
Apart from the PCMH structure, as described above, the second main PCMH 
focus area in the literature is outcomes. However, outcomes regarding PCMH models are 
mixed and more evidence related to clinical and economic outcomes is needed.26,27 A 
recent study reported positive outcomes from a PCMH, particularly with enhanced 
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prevention, chronic disease management, patient satisfaction and cost reduction.28 Other 
studies however, found no significant improvements in hospitalizations and emergency 
department (ED) visits.29,30 Models of care that involved pharmacists have been shown to 
improve outcomes of various diseases, such as hypertension, diabetes, asthma, renal 
disease and cardiovascular disease.4,23,31 Specifically, regarding PCMHs studies that 
focused on diabetes, early demonstration projects revealed encouraging evidence with 
improvements in HbA1c, blood pressure, LDL cholesterol, hospitalizations, readmissions 
and emergency room visits.32 In a review of pharmacists’ interventions and diabetes 
outcomes, the greatest improvements in HbA1c were observed when pharmacists were 
incorporated in collaborative practice models.33  
 
Pharmacists integrated in PCMHs are valuable resources to improve diabetes 
management, particularly with quality of care and safety of medications, both of which 
can translate into cost savings. Although the literature on PCMHs is growing, few studies 
have described the structure of medical homes, or the responsibilities and workflow of 
the pharmacists in these entities. Similarly, studies that report clinical, utilization and 
economic outcomes are scarce, and when available, results are mixed. This suggests a 
need for more research in this area to provide a better understanding of the impact of 
pharmacists on diabetes outcomes in underserved populations, who generally have poorer 
outcomes. 
 
Therefore, the goal of this study is to describe the implementation of pharmacists-
integrated PCMH in federally qualified health centers (FQHCs), which primarily provide 
care to underserved patients. Descriptions on successful application of the PCMH 
concepts will help with the refinement of the model, and more evidence of the value of 
such practices may support future development PCMHs. 
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1.2  LITERATURE REVIEW 
New models of care are growing and development in this area, including 
integration of pharmacists in team-based management, has been increasingly documented 
in the literature. This literature review examines several concepts applied by integrated 
models of care, with specific attention to the principles of patient-centered medical 
homes (PCMHs). The roles and responsibilities of pharmacists are described and the 
impact, outcomes, challenges and barriers of pharmacists’ integration in these structures 
are discussed. The review also encompasses the burden of diabetes mellitus in 
underserved populations, who could potentially benefit from the pharmacist services in 
PCMHs. 
1.2.1 Current Trends in Integrated Models of Care 
Health care in the US has generally been provided through the fee-for-service 
system and years of evolvement have resulted in a complex structure that is commonly 
described as expensive with poor quality of care. The system has been described as 
fragmented with providers being incentivized by a payment structure that rewards 
volume, growth and intensity.22,34 The traditional approach provides direct access to 
individual health care providers but has discouraged active patient involvement in the 
management of their health condition, and it has compromised communication across 
different providers in chronic care.35 With these issues being identified in the last decade, 
there have been initiatives to promote integrated care systems to address weaknesses of 
the existing system. The general idea of integrated care is that physicians, specialists, and 
hospitals coordinate patient care by sharing patient information and preventing duplicate 
or unnecessary tests and treatments.22,36 Since medical care is delivered via 
interdependent arrangements between different health care providers that complement 
each other, collaboration between various parts of the system is vital to the effective and 
efficient delivery of health care services.37  
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Integrated care is one method to organize health care and it has various delivery 
mechanisms. The World Health Organization defined integration as “The management 
and delivery of health services so that clients receive a continuum of preventive and 
curative services, according to their needs over time and across different levels of the 
health system.”38 Integrated care has also been defined from the context of a “bottom-up” 
approach, i.e., one that is structured according to the needs of patients. Other definitions 
of integrated care include: a package that delivers multiple services under one roof, 
services that extend over time to provide continuity of care, vertical integration of health 
care services which is overseen by a manager, or a team with integrated policy and 
management.38 When administered appropriately, integrated care can lead to 
improvement in quality, accessibility, safety and cost-effectiveness of health care.37,39 In 
summary, the traditional practice of medicine where the physician is the sole decision 
maker is changing to a pragmatic approach that involves patients’ concerns and 
participation in the health care decision-making process.38 
 
The concept of integrated and patient-centered care has been growing and the 
pursuit of identifying criteria for successful models is ongoing. Enthoven A.C (2009) 
reported that a successful integrated delivery system should encompass the following 
principles: shared organizational commitments, physician leadership, patient-
centeredness with a focus on population health, coordinated care and information, 
appropriate financial incentives, evidence-based medicine, efficient electronic health 
records, appropriate physician-patient ratio, and continuous innovation.40 Early favorable 
outcomes from pioneer models of integrated care such as Kaiser Permanente and 
Cleveland Clinic have also prompted the recent health care reform efforts to encourage 
initiatives such as Accountable Care Organizations (ACOs), which emphasize the value 
of integrated care.22 
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1.2.1.1 Accountable Care Organizations (ACOs) 
Accountable Care Organizations were introduced in 2010 along with the 
Affordable Care Act (ACA) with the aim to encourage providers, across different settings 
such as physician offices, hospitals and long-term care facilities, to work together with a 
focus on patients’ needs. The ultimate goal of ACOs was to achieve high quality care 
with lower costs by implementing a continuum of care.36 Physicians have long worked in 
coordinated care in closed system Health Maintenance Organizations (HMOs), where the 
health plan and providers serve only their members.22,34 ACOs extend this concept with a 
lift of the restricted network in HMOs to allow patients to receive care from ACOs or 
non-ACO providers.22,34,36  
 
To incentivize the provision of high quality care at lower costs, the Centers for 
Medicare & Medicaid Services (CMS) provide ACOs with a Shared Savings Program. 
This program measures the performance and targets of the patient population under the 
ACO, and directs savings from improved outcomes to the providers.22,36 With the 
financial incentives, ACOs are motivated to share information as a large integrated 
network and to emphasize preventive care as accountabilities for patients are shouldered 
upon the ACOs.41 A variety of providers can be part of ACOs – from large integrated or 
multispecialty group practices such as Kaiser Permanente or Cleveland Clinic that are 
readily incorporated as ACOs, to hospital-based systems and small independent physician 
practices.41,42 Two examples of successful integrated health care systems, Kaiser 
Permanente and Cleveland Clinic, are highlighted below. 
1.2.1.2 Kaiser Permanente 
Founded in 1945, Kaiser Permanente has grown to be the largest nonprofit 
integrated health care delivery system in the United States.43,44 As a part of Kaiser 
Permanente, Kaiser Foundation Health Plans serves as the payer, and it uses the 
capitation method. This enables Kaiser to have both roles of payer and provider 
(including laboratory and pharmacy), which can enable them to better account for the 
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clinical care, quality improvement and resource management throughout the system.40,44,45 
The organization generally provides multidisciplinary services under one roof, with 
doctors from primary, secondary and tertiary care settings sharing the budget and 
responsibilities for all care.44,46,47 The system is stratified to provide appropriate care 
according to the complexity of the services needed, with the philosophy that a strong 
primary care is the base for efficient patient management.44  
 
Kaiser is well recognized for its electronic medical record system, which 
promotes team work between providers, facilitates communication with the patients and 
monitors quality performance. Some of the latest innovations include evidence-based 
electronic prescribing and population disease registries that can track patients with 
chronic conditions with the purpose of early detection and prevention.44,48 Another driver 
of collaboration and coordination in Kaiser is the culture of internal transparency, which 
promotes sharing of information and peer reviews among the physicians. Physicians also 
have high autonomy in both clinical protocols and management of the health plan.44 
 
An interesting comparison between Kaiser Permanente and the National Health 
Service (NHS) in the UK revealed that Kaiser achieved better performance on the 
following: more comprehensive and convenient primary care services, faster access to 
specialist services and hospital admissions, and shorter length of acute bed days.49 
Examples of other positive population health outcomes from Kaiser programs include: 
reduction in relative risk of death from cardiac events, improvement in the blood pressure 
and blood glucose control, and reduction of hospitalization rates for myocardial 
infarction.44 
1.2.1.3 The Cleveland Clinic 
Started in 1921, Cleveland Clinic is a another example of a nonprofit 
multispecialty academic medical center that integrates clinical and hospital care with 
research and education.50 Based in Cleveland, Ohio, the network has expanded globally to 
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more than 70 countries.51 The physician-led Cleveland Clinic model emphasizes patients’ 
needs and long-term patient-doctor relationships.50–52 
 
Among their success stories are: same day access, reduction in wait time for new 
appointments to 7 days and a patient-tracking GPS system that reduced 20% of office 
visit wait times.52,53 Doctors and nurses have access to the patients’ electronic medical 
records (EMRs) regardless of the patients’ location in tertiary or primary care. 
Interestingly, there is also Critical Care Transport, which consists of air and land 
transportation equipped with travelling medical personnel on standby to transfer patients 
from different countries and states to receive advanced care.52 
 
Cleveland Clinic has been commended regarding their transparency efforts. 
Clinical outcomes from the institution such as mortality, complication rates and patient 
satisfaction are published annually.51,52,54 Real-time, transparent snap-shots of key 
performance metrics are made available to inform and align providers, and to ensure 
protocols are applied consistently throughout the system.52 Cost is also tracked and 
analyses are conducted to enhance cost-effectiveness. Examples of these efforts include: 
replacement of a $400 staple with a $5 stitch for suturing, and improvement of sterile 
conditions to reduce catheter-related and urinary tract infections.55 Research and 
education are also integral to the clinic and findings are shared to inform the health care 
community.51 
 
Similarities of the successful models discussed include seamless systems that 
mutually depend on different specialties, continuous innovation and having a strong 
primary care. The concepts from these exemplary systems are also shared by primary 
care institutions – that are commonly called medical homes. These types of health care 
models are further described in the following sections. 
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1.2.2 Concept of Medical Home in Primary Care 
Often interchanged with terms such as advanced medical home, advanced primary 
care practice, patient-centered medical home or health home, the concept of medical 
home refers not to a physical structure but an approach for providing comprehensive and 
coordinated primary care.21,24 The medical home model has been stressed by policy 
makers in recent years as one of the methods to address challenges of the US health care 
system, which include poor access and suboptimal primary care.56,57  
 
Among the reasons for the suboptimal primary care system is that careers in 
primary care, such as in general internal medicine and family medicine, are becoming 
less popular among medical graduates. Consequently, there is a shortage of primary care 
physicians, who are faced with challenges in providing quality care for the patients. The 
concept of a medical home has been proposed to overcome this issue as many physicians’ 
responsibilities can be delegated to other health care practitioners such as nurses, medical 
assistants and pharmacists through an integrated team structure.56–58 Additionally, 
evidence supports that access to primary care services improves health outcomes, 
regardless of the supply of primary care physicians.59 
 
The medical home concept, which is comprised of primary care management, 
person-centered, problem-solving, comprehensive, community, and holistic approaches is 
also advocated by health care systems around the world including Australia, Canada and 
Europe.60–62 In the US, pediatricians pioneered the medical home concept in 1967 with the 
idea of having a centralized medical record of children with special health care needs.19,21 
Later in 2007, four primary care physician societies developed the Joint Principles of the 
Patient-Centered Medical Home, which became the main guide for further development 
of the model, as discussed next.21 
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1.2.2.1 Patient-Centered Medical Home (PCMH) 
PCMH is a coordinated care model focused on patient needs through continuous 
patient-physician relationships, as opposed to the conventional episodic care.19,20 The core 
of the system is a team of primary care providers, from nurses to frontline staff who are 
led by clinicians, complemented by evidence-based medicine and information technology 
to provide health care with optimal quality and safety.19,21 While the ACO model targets 
accountability and alignment of incentives for providers, the PCMH model focuses on the 
primary care structure, as both are important building blocks for health delivery system 
reforms.63 
 
According to the Joint Principles of the Patient-Centered Medical Home,21 the 
pillars of PCMH are:  
1)  Personal physician who provides continuous care to each patient 
2)  Physician directed medical practice that leads a team that is responsible 
for the patients 
3)  Whole person orientation where the physician should provide care for all 
patients’ health care needs or make referrals when necessary 
4)  Care is coordinated and/or integrated across the complex health care 
system from hospitals and nursing homes, to the patient’s community 
5)  Quality and safety through patient-centered partnerships, evidence-based 
medicine, accountability, patients’ participation in decision-making, 
optimal use of information technology, and quality recognition process 
6)  Enhanced access such as open scheduling, expanded hours and 
innovative communication means 
7)  Payment that recognizes the added value from PCMH 
 
To elaborate on these principles, patient-centeredness is being respectful of 
patients’ needs and preferences, ensuring understanding and involving patients’ 
participation in the care plan and self-management.64 Together with the long-term 
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relationship with a primary care physician, the patient’s care is personalized.20 Next, 
effective team-based care allows each non-physician staff member to maximize their 
professional skill sets to complement each other.64,65 Cross-training of staff helps with the 
ability of the practices to overcome staff absences and turnover.64 As a consequence, 
physicians can focus on the management of complex medical conditions.65 Discernibly, 
effective communication among team members and outside providers is critical for 
coordination as poor communication may lead to duplication of services, as well as with 
unnecessary anxiety and financial costs for the patients and caregivers.64,65 
 
For care coordination, health information technology (HIT) is central to 
synchronize patient records, referrals and to provide transitions of care (e.g., from 
hospitalization to outpatient follow up).48,65 Population health management is feasible 
with the assistance from electronic patient registries to shortlist patients according to the 
targeted conditions as determined by the team.52,65 Systematic approaches to monitor and 
improve quality and safety can be embedded in routine activities of the team members, 
facilitated by HIT.64,65 
 
Another component that contributes to patient-centeredness and care coordination 
is enhanced access. Enhanced access refers to the provision of clinical advice, as well as 
insurance information during and after office hours.20,64 Some other innovations that 
encompass enhanced access include same-day scheduling, and email and telephone 
visits.57 One health care system’s efforts to improve patient-centered access involves a 
website that allows communication with physicians through secured e-mail, EMR and the 
provision of health promotion information.66 Payment restructuring by: modifying the 
traditional fee-for-service with addition of new payment codes, instituting shared savings 
models that allow sharing of costs saved by decreased utilization, and incorporating fixed 
per member per month payments have all been used to enhance the sustainability of the 
PCMH model. However, there is yet a consensus on optimal payment models.65,67,68 
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The concept of PCMH is still in its developmental stage and early evaluations of 
the programs revealed generally positive but mixed outcomes particularly on quality 
measures.65,69 More evidence by transparently testing the model in different environments 
is needed to determine whether PCMHs have a positive impact on patient-related 
outcomes. This evidence is needed before the concept will be fully embraced by various 
stakeholders.69,70 
1.2.2.2 PCMH Standards According to National Committee for Quality Assurance 
(NCQA)   
The Joint Principles publication (see section 1.2.2.1) was subsequently adopted by 
NCQA as Standards and Guidelines for Physician Practice Connections® - Patient-
Centered Medical Home (PPPC-PCMHTM) in 2008.19,58 In 2014, NCQA updated the 
PCMH standards and guidelines to include the following six standards: Patient-Centered 
Access, Team-Based Care, Population Health Management, Care Management and 
Support, Care Coordination and Care Transitions, and Performance Measurement and 
Quality Improvement. A brief description of each standard is detailed in Table 1.1. To 
acquire three years of NCQA recognition, primary care facilities must achieve minimum 
scores as determined by the NCQA guidelines. Three recognition levels are available, 
depending on the points acquired by the facility, with level 3 being the highest.19  
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Table 1.1 Summary of NCQA PCMH 2014 Standards 
Standard Summary of Requirements  
1. Patient-Centered 
Access 
The practice provides 24/7 access to team-based care for both 
routine and urgent needs of patients/families/caregivers.  
2. Team-based Care The practice provides continuity of care using culturally and 
linguistically appropriate, team-based approaches.  
3. Population Health 
Management 
The practice provides evidence-based decision support and 
proactive care reminders based on complete patient information, 
health assessment and clinical data.  
4. Care Management 
and Support 
The practice systematically identifies individual patients and 
plans, manages and coordinates care, based on need.  
5. Care Coordination 
and Care 
Transitions 
The practice systematically tracks tests and coordinates care 






The practice uses performance data to identify opportunities for 
improvement and acts to improve clinical quality, efficiency and 
patient experience.  
Source: Adapted from Standards and guidelines for NCQA’s patient-centered medical home (PCMH), 
National Committee for Quality Assurance, 2014, page 14. 
1.2.2.3 Implementation of PCMH 
The Joint Principles and NCQA standards echo the increasing value of PCMH. 
The passing of the ACA reflects efforts to improve the quality and safety of health care 
and a priority to achieve this through PCMHs has also been emphasized.4 
Correspondingly, the potential of PCMHs in providing high quality care while reducing 
health care related costs has been embraced by several groups including ACOs. The 
PCMH model was also adopted by the Veterans Health Administration (VA) as the 
Patient Aligned Care Teams (PACTs) in 2010, and introduced by the Centers of 
Medicare and Medicaid Services (CMS) as PCMH demonstration programs with the goal 
to slow spending growth.68,71 Likewise, community health centers and Federally Qualified 
Health Centers are being transformed into PCMHs.19 As of May 2015, there are more 
than 10,000 practices recognized as PCMHs by NCQA.72  
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Despite that, the operationalization of the PCMH principles varies according to 
the interpretation of the institutions and implementation of PCMH differs from a narrow 
range that focuses on a specific clinical condition, to a broad approach to include PCMH 
in the institution across all conditions and patients.28,73,74 Although the growing literature 
on PCMH generally reported positive outcomes, results are mixed.28 Questions on the 
best definition, correlation between the degree of implementation and outcomes, and 
approach for transformation into PCMH still needs exploration.75  
 
Regarding the PCMH transformation initiative, a qualitative analysis of the CMS 
National Demonstration Project aptly described practices transitioning into PCMH 
models.76 Among the 36 practices with diverse geography, size, age, and ownership 
arrangements, transformation characteristics frequently described include: efficient use of 
EMR, effective communication, and role expansion of other medical staff such as 
medical assistants and nurse practitioners. In one large practice, authors also mentioned 
the inclusion of a clinical pharmacist on the health care team. 
1.2.2.4 Outcomes of Integrated Care 
Some publications, mainly studies from pilot and initial trials of PCMH 
implementation have reported encouraging outcomes on staff productivity, and health 
and utilization outcomes, therefore providing initial support for the viability of the model. 
The Veterans Health Administration (VA), the largest integrated US health system, with 
more than 5 million patients nationwide has demonstrated support for the PCMH 
structure. Two years after initiation in 2010, there were significant changes in utilization 
such as decrease in in-person primary care physician visits (53 to 43 per 100 patients per 
calendar quarter; p<0.01), increase in telephone care (2.7 to 28.8 per 100 patients per 
quarter; p<0.01), and improvement in post hospitalization follow-up (6.6% to 61% of VA 
hospital discharges).77  
 
 16 
Other studies reported mixed findings of improved outcomes in various 
dimensions and limited improvement in other outcomes. For instance, the evaluation of 
patient outcomes 26 months after the National Demonstration Project of PCMH 
transformation found associations between the adoption of PCMH components with 
quality of care including improved access (p=0.04), better prevention (p=0.001) and 
quality of care scores (p=0.007). However, there were no improvements in chronic care 
scores and patient-rated outcomes (patient empowerment, general health status, 
satisfaction with the service relationship coordination of care, comprehensiveness of care, 
personal relationship over time, and global practice experience).75  
 
Three other studies also reported mixed utilization outcomes. One study found 
associations between decreased ED visits and PCMH implementation while two other 
studies found no significant changes in ED visits. The first study include children with 
asthma and reported reduced rates of ED visits (incidence rate ratio = 0.93; 95% 
confidence interval = 0.89-0.97).78 The second study, which was conducted in New York 
State, compared health care utilization outcomes in facilities with and without a PCMH 
structure. In this study, there were no significant differences for ED visits, primary care 
visits, radiology tests, laboratory tests, admissions, or readmissions. However, this study 
reported positive finding of fewer specialist visits in the intervention group one year after 
implementation of PCMH.29 A third PCMH implementation study reported no significant 
changes in ED visits, inpatient admissions and quality measures.30 Finally, a review that 
evaluated medical home outcomes published between 2007 and 2010, revealed decreased 
utilization of the ED and improvement in quality. This review however, reported the lack 
of evidence for enhanced patient or family experiences.73 
 
One health care system (Group Health) with 20 primary care clinics in 
Washington State has been implementing PCMH reforms since 2002. These reforms 
include same-day appointment scheduling, direct access to specialists, primary care 
redesign, physician compensation, and an EMR with a patient web portal to enable 
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patient e-mail, online medication refills, and record review.79 Despite the success in 
improving access, productivity and patient satisfaction, physicians’ workload increased 
and resulted in decreased clinical quality.80–82 Consequently, in 2006, the health care 
group implemented redesigns to address the problem at one PCMH prototype clinic in 
Seattle.79,83 The health care system reported hiring more staff according to this ratio; for 
every 10,000 patients; 5.6 physicians, 5.6 medical assistants, 2.0 licensed practical 
nurses, 1.5 physician assistants or nurse practitioners, 1.2 registered nurses, and 1.0 
clinical pharmacist. The follow-up comparison between the PCMH prototype clinic and 
control clinics showed reductions in ED visits and hospitalizations, and improvements in 
patients’ experiences, quality and clinician burnout. Overall, after 2 years of PCMH 
prototype implementation, the estimated total savings was $10.30 per patient per month 
and the return on investment was $1.50 for every dollar spent to implement the PCMH.83  
 
Conversely, one study which examined transitioning of small and solo primary 
care practices into PCMH models reported that although there are significant, modest 
improvements in some indicators of quality and efficiency, cost savings were not 
observed.84 On the other hand, a recent study found that both higher levels and amount of 
change in PCMH implementation (based on NCQA scores) are related to higher quality 
of care and preventive services utilization, while higher levels of practice implementation 
were associated with lower overall medical and surgical costs.28 More evidence on the 
effectiveness and sustainability of PCMH are therefore needed, especially regarding 
integration of pharmacists. 
1.2.3 Roles of Clinical Pharmacists 
The Institute of Medicine highlighted that optimal use of pharmaceuticals, the 
most common medical intervention, is a critical component in improving the national 
health care system.1 However, drug related problems such as medication adherence and 
medication errors have long plagued modern medicine. Wilson et al. (2007) described the 
scenario of nonadherence to medication as a result of poor communication between 
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patient and prescriber. More than half of the elderly population in the US have more than 
one physician, but discussions with prescribers regarding the issues of multiple 
medications, or nonadherence due to side effects or costs are limited.85 On a related note, 
conservative estimates showed that at least 1.5 million unnecessary adverse drug events 
in the US annually is a preventable problem that costs at least 200 billion dollars each 
year.2 Transformation in the health care system is vital and involvement of various 
stakeholders, including patients, is needed to ensure success.1 
 
The term “pharmaceutical care” emerged to the forefront by Hepler and Strand in 
1990 and the American Society of Health-System Pharmacists vowed to focus on 
pharmaceutical care in 1993 as part of an effort to improve medication use and patient 
safety.86,87 It is the “direct, responsible provision of medication-related care for the 
purpose of achieving definite outcomes that improve a patient’s quality of life.”87 With 
that said, pharmacists, being the medication experts in optimizing therapeutic outcomes, 
are the most suitable health care practitioners to address the issues above. 
 
According to the American College of Clinical Pharmacy (ACCP), besides 
embracing the philosophy of pharmaceutical care, clinical pharmacy involves in-depth 
understanding of medications, application of evidence-based therapy, and accountability 
for managing medication therapy to achieve therapeutic goals.88 Throughout the years, 
training for clinical pharmacists has been enhanced and various pharmacist-provided 
services to optimize medication therapy in direct patient care settings have expanded.88,89 
In 2003, structured clinical pharmacy services, commonly referred to medication therapy 
management (MTM), became eligible for Medicare reimbursement and pharmacists were 
specifically named as a provider for these services.89 
1.2.3.1 Medication Therapy Management (MTM) 
MTM is a systematic process that assesses and evaluates patient’s complete 
medication therapy regimen with focus on the patient, rather than the product.18 The 
 19 
comprehensive structure involves coordination with other practitioners to manage all 
other medications and medical conditions that the patient has and also empowers patients 
to actively manage their medications.14,18 The provision of MTM varies according to the 
needs of the patients and settings but is typically conducted face-to-face for optimal 
interaction. Follow-up intervals also depend on the complexity of each patient; hence, 
personalization of the service.18  
 
The five core elements according to the service model advocated by 8 pharmacy 
associations in the US are summarized below: 
1. Medication Therapy Review (MTR): A systematic process of collecting patient-
specific information, assessing medication therapies to identify medication-related 
problems, developing a prioritized list of medication-related problems, and 
creating a plan to resolve them. 
2. Personal Medication Record (PMR): A comprehensive record of the patient’s 
medications (prescription and nonprescription medications, herbal products, and 
other dietary supplements). 
3. Medication-Related Action Plan (MAP): A patient-centric document containing 
a list of actions for the patient to use in tracking progress for self-management. 
4. Intervention and/or Referral: The pharmacist provides consultative services 
and intervenes to address medication-related problems; when necessary, the 
pharmacist refers the patient to a physician or other health care professional. 
5. Documentation and Follow-up: MTM services are documented in a consistent 
manner, and a follow-up MTM visit is scheduled based on the patient’s 
medication-related needs, or the patient is transitioned from one care setting to 
another.  
 
MTM has been implemented in a number of ways to manage the drug related 
problems according to the needs of the institution and improved outcomes have been 
reported. A retrospective study that examined outcomes among underserved diabetes 
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patients found higher adherence and lower HbA1c among patients who received 
pharmacist-directed MTM when compared with usual care.90 A discharge MTM program 
in an extended care hospital had success in decreasing the number of discharge 
medications and readmission rates.91 Interventions provided through telephone MTM 
program have also been reported to reduce medication-and health-related problems, and 
the associated costs.92 
 
On the contrary, a recent meta-analysis found that there is insufficient evidence 
regarding the impact of MTM on health outcomes, although there is weak evidence on 
improvement in adherence and health care costs.93 To maximize outcomes from clinical 
pharmacy services, it is important to prioritize services that have the most impact on 
patient health and is most need by the community. In other words, having a targeted 
approach on the disease state is recommended.61,94 Typically, the positive effects of MTM 
are more significant for costly conditions such as diabetes, cardiovascular disease, asthma 
and cancer. MTM effectiveness also increases with disease severity, higher number of 
comorbidities and higher number of medications.14,35 Consistent with this, a review of 
randomized controlled trials that evaluated the integration of MTM in a primary care 
medical home suggested that MTM is most efficient when patients with specific 
therapeutic problems are targeted, and when combined with effective communications 
and patient follow-up.95 
 
 The interventions provided by MTM are generally well received by providers and 
patients. Physicians appreciate the skills of pharmacists as part of the clinical team, and 
they have emphasized the importance of efficient communication and concise 
recommendations.96 Regarding patients, they generally perceived personalized 
medication records and action plans, referral to other providers, and improved 




It is important to realize that MTM is an evolving field, with constant challenges 
and opportunities for researchers and policymakers. With the growing evidence of the 
relationship between MTM interventions and outcomes, the prospects of MTM expansion 
into integrated care is positive.93 
1.2.3.2 Clinical Pharmacy Practice in Primary Care 
Primary care typically provides the first contact between patient and providers. In 
comparison to specialist and tertiary care, patients in primary care are more likely to 
present themselves without an associated diagnosis and therefore, it is more common to 
have diagnostic uncertainty and encounter complex drug regimens in primary care.61 For 
this reason, the World Medical Association (WMA) has identified primary care as the 
best access point to coordinate care for chronic conditions and to prevent medication 
errors.99 Accordingly, the roles of clinical pharmacists, as key medication management 
providers, can have a significant impact on the delivery of primary care.23 
 
Justified by the growing evidence that showed the value of pharmacists in team-
based care models in acute care or outpatient settings, the notion of pharmacists working 
directly with primary care physicians has been developing and expanding.23,61 The 
approval of specialty residency programs in ambulatory and community care pharmacy in 
2009 by the Board of Pharmaceutical Specialties further strengthens the significance of 
clinical pharmacy practice in primary care.100 Moreover, pharmacists have been 
recommended to be responsible for the continuity of pharmaceutical care when patients 
are transitioning from inpatient to outpatient care.101 
 
The approach of clinical pharmacy services in primary care incorporates the 
concept of MTM, namely providing patient-centered medication therapy assessments, 
and may include other services such as ordering laboratory tests and medication 
adjustments.23 For the latter purposes, written guidelines for authorizing and delegating 
the pharmacists’ roles can be accomplished through collaborative drug therapy 
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management arrangements. The functions, procedures and decision-making criteria 
should be clearly defined.24 Thus, collaborative practice agreements are important 
facilitators to optimize the roles of pharmacists. The agreements determine pharmacists’ 
levels of autonomy in service provision, which may range from only monitoring 
medications and conditions to changing prescribed medications and prescribing 
medications.35 More importantly, pharmacists’ collaborative efforts to manage patients’ 
therapy, such as medication therapy initiation and adjustment, may help reduce physician 
workload.102  
 
In primary care settings, clinical pharmacists can provide individual or group 
consultations through direct or telephone interventions, and in various settings such as 
primary care offices, outpatient clinics, home visits, work-site health programs, senior 
centers, and community pharmacists’ practices.23 Apart from MTM services, pharmacists 
are often involved in preventive care such as immunizations, monitoring population 
registries together with the medical team, and administrative roles such as PCMH 
accreditation activities.56 Besides collaboration with other health care providers, 
pharmacists also have sustained relationships with patients’ families and caregivers.23  
1.2.3.3 Pharmacist Involvement in PCMH 
PCMH emphasizes provision of individualized medication assessment and 
tailored solutions.14 Studies have shown that pharmacists are valuable resources for drug 
information and medication management when integrated into physician practice 
settings.56 In a PCMH establishment, the pharmacist’s roles include24: 1) Identifying, 
resolving, preventing, and monitoring medication use and safety problems; 2) Reducing 
polypharmacy and optimizing medication regimens on the basis of evidence-based 
guidelines; 3) Recommending cost-effective therapies; 4) Designing tailored adherence 
and health literacy programs; 5) Developing patient medication action plans with self-
management goals; 6) Communicating medication care plans to patients, providers, and 
other entities in the patient’s health care delivery system.  
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However, pharmacists are often underused despite their training and expertise in 
medication management.23,103 Recent initiatives that recognized the value of pharmacists 
include the Patient Safety and Clinical Pharmacy Services Collaborative (2008) and 
Patient-Centered Primary Care Collaborative (2012), that emphasized the importance of 
pharmacist integration and comprehensive medication management service.14,103  
 
As pharmacy services expand, successful examples of pharmacists’ contributions, 
outcomes resulting from the integration of pharmacists into primary care practices and 
lessons learned can inform and motivate other pharmacists to participate in PCMH.4 A 
study based in Michigan described the integration of pharmacists into PCMH structure at 
eight general medicine practices.35 Pharmacists were positioned to substitute various 
aspects or augment physician care, help achieve quality indicators and increase revenue 
through billing of clinical pharmacy services. The inclusion of pharmacists in the PCMH 
model provided an opportunity to standardize ambulatory pharmacy care across different 
sites, which were operating in a ‘silo’ prior to PCMH implementation. Further, PCMH 
pharmacists were added into five other health centers that did not have pharmacists. In 
their model of care, pharmacists were responsible for evaluating and optimizing 
therapeutic regimens to achieve treatment goals for diabetes, hypertension, 
hyperlipidemia, and polypharmacy. Patients were identified through proactive screening 
of patient registries, or physician referral. Pharmacists discussed the patients’ conditions 
with their physicians and managed the diseases according to clinical practice guidelines. 
In this study, the mean number of patients ranged from 2.2 to 6 patients per half-day 
clinics (range from 1 to 6). 
 
It is noteworthy to highlight another pharmacist-integrated PCMH in North 
Carolina (Mountain Area Health Education Family Health Center) that has been 
recognized as a level 3 PCMH by NCQA.104 The Department of Pharmacotherapy is 
embedded in the family medicine clinic and pharmacists provide MTM, anticoagulation, 
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and osteoporosis clinical services. The structure of the PCMH is led by primary care 
physicians and supported by team members which include pharmacists, nurses, 
behavioral medicine providers, physician assistants, nutritionists, Spanish interpreters, 
and case managers. Medication reviews are typically conducted for complex medication 
regimens, diabetes management and medication assistance. By having accountability for 
patients as part of the team, pharmacists contribute to the joint principles of PCMH. 
Descriptions of how pharmacist activities fulfill the Joint Principles of PCMH21 are 
illustrated in Table 1.2. 
Table 1.2 Examples of pharmacist activities based on the Joint Principles of PCMH 
 
Source: Adapted from “Integration of pharmacists into a patient-centered medical home”, by M.A. Scott, B. 
Hitch, L. Ray and G. Colvin, 2011, Journal of the American Pharmacists Association, page 163. 
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1.2.4 Integration of Pharmacists in Team-based Care  
The importance of team-based expertise in providing quality health care cannot be 
underestimated.17 The literature shows that team care with pharmacist-provided direct 
patient care yields positive therapeutic and safety outcomes.105 Therefore, pharmacists are 
well suited health care practitioners to work in interdisciplinary primary care teams, 
providing their expertise in comprehensive medication management, particularly for 
patients with chronic conditions.14,23  
 
Different approaches have been applied to integrate pharmacists into collaborative 
care. Clinical pharmacy services can be set up in various settings such as physician 
offices, hospital-based outpatient clinics, and pharmacies.106 Pharmacists can also be 
engaged on a full-time or part-time basis, providing services directly in the medical 
practice facility or in community pharmacies through contracts and collaborative 
agreements.56 When possible, the setting to provide pharmacy services should be near the 
referring physicians as the proximity promotes collaboration, enhances communication 
and encourages referrals.106 
1.2.4.1 Integration of Pharmacists in PCMH  
The development of a PCMH is unique to the needs of the institution, and thus the 
integration of pharmacists into the structure should be tailored accordingly for 
success.94,106 Pharmacists can be employed as full-time staff to conduct consultations in 
the PCMH practice itself, or contracted as a part-time pharmacist to provide services 
around the community, which allows for more flexibility.24,107 An advantage of having in-
house pharmacists in the medical home is that primary care providers can omit referral to 
medical specialists for medication adjustments as pharmacists can perform medication 
management more cost effectively.23  
 
Pharmacist can provide services externally through embedded, regional, 
contracted and external models. In the embedded model, pharmacists can practice in the 
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PCMH through partnership with hospital pharmacy or pharmacy schools that may 
involve training of Pharm.D. students and pharmacy residents. In the regional model, the 
contracted pharmacist typically works in a health system or health plan that serves 
several PCMHs in the region. Contracted and external models are suitable for smaller 
physician practices as pharmacists are not typically employed full-time and there is more 
flexibility for patients in terms of when and where services are provided.24 The external 
model also allows for the participation of community pharmacists in PCMH.24 
 
In terms of clinical pharmacy services integration, the pharmacist may meet 
patients prior to, during or after the primary care appointment.24 For instance, pharmacists 
may see patients via a pre-visit approach in collaboration with the medical home team 
and later share the care plan recommendations with the physician before or after a 
physician visit.23 Patients who did not reach therapeutic goals, were on high risk 
medications, with complex drug regimens, or have multiple prescribers for MTM 
services, can be identified by pharmacists, or referred by providers for a separate follow-
up pharmacist visit.24 
 
There are many ways for physicians to refer patients to pharmacists. Generally, 
targeted referrals through physician self-initiated referral or predetermined criteria from 
databases are more efficient in selecting patients in need of the services.24,61 Findings 
from a Canadian project suggest that targeted physician referral of patients with specific 
needs is more effective than referral of patients with at least 5 medications.61 Referrals 
can also come from any team member for issues relating to drug therapy.104 Again, the 
best referral method depends on the needs of the institution and the pharmacist should 
plan for the best strategies together with the PCMH team.61 
 
Regardless of the integration methods, details of job descriptions, referrals, 
documentation, time and place of service should be clearly defined.94 The importance of 
these elements has been highlighted by a case study in Chicago. The pilot PCMH 
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included a pharmacist in an administrative position for the PCMH operations and 
analytics committee. This helped with the development of the pharmacist’s role and it 
also built physicians’ trust. The approach was described as very successful, to the extent 
that referrals to the pharmacist were subsequently higher than what could be met. 
Collaborative practice agreements were also in place, allowing pharmacists to initiate, 
discontinue or titrate medications based on patient results and tolerance.108  
1.2.4.2 Impact and Outcomes of Clinical Pharmacists in Integrated Care 
Pharmacist services are usually provided for chronic diseases like hypertension, 
diabetes and asthma. There are also clinical pharmacy services provided for conditions 
such as osteoporosis, epilepsy and infection, although this is less common. Clinical, 
utilization and costs outcomes that compared pharmacist-integrated models with that of 
usual care reported mixed results that lean towards outcomes improvements with 
pharmacy services. 
 
One randomized control trial published in 2008 (n=463) compared physician-
pharmacist collaboration and usual care for the control of hypertension. Subjects 
receiving the intervention achieved significantly lower primary outcomes of systolic (p= 
0.007) and diastolic (p=0.002) blood pressures compared to the control group (137/75 
mmHg vs. 143/78 mmHg, respectively). Secondary measures at 12-month follow-up 
showed significantly higher blood pressure goal attainment of <140/90 mmHg, higher 
total office visits, fewer physician visits, and more prescriptions for antihypertensive 
medications for patients who received collaborative care. There were minimal differences 
between the groups in hypertension-related knowledge, medication adherence, quality of 
life, and satisfaction.109 
 
An MTM program focused on hypertension and dyslipidemia in Asheville 
reported positive clinical (n=565) and economic (n=620) outcomes. The pharmacists 
provided cardiovascular or cerebrovascular risk reduction education, long-term follow-
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up, monitoring and recommendations to physicians. These interventions significantly 
improved cardiovascular health indicators over the course of the study: mean systolic 
blood pressure (137.3±16.85 to 126.3±14.20 mmHg); mean diastolic blood pressure 
(82.6±11.62 to 77.8±9.67 mmHg); percentage of patients at blood pressure goal (40.2% 
to 67.4%); mean low-density lipoprotein (LDL) cholesterol (127.2±36.60 to 108.3±32.06 
mg/dL); percentage of patients at LDL cholesterol goal (49.9% to 74.6%); mean total 
cholesterol (211.4±45.70 to 184.3±38.55 mg/dL); and mean serum triglycerides 
(192.8±171.41 to 154.4±88.35 mg/dL). There were no differences in mean high-density 
lipoprotein (HDL) cholesterol (48±13.35 to 46.6±12.24 mg/dL). However, over the 6-
year study period, the cardiovascular or cerebrovascular event rate declined to almost half 
of the baseline rate (77 per 1,000 person–years to 38 per 1,000 person–years).110 
 
Regarding economic outcomes, mean cost per cardiovascular or cerebrovascular 
event in the study period was $9,931, compared with $14,343 during the historical 
period. Although medication use increased nearly threefold, related medical costs 
decreased by 46.5%. Cardiovascular or cerebrovascular related medical costs also 
decreased from 30.6% of total health care costs to 19%. The results of this study 
demonstrated sustainable outcomes from pharmacist interventions for as long as 6 
years.110 
 
Clinical pharmacy services integrated into another PCMH structure with an 
osteoporosis clinic contributed to the increase of appropriate calcium and vitamin D use 
from 30% at baseline to 99% at follow up.104 Another interesting pilot study involving 
pharmacist intervention, which combined traditional MTM and lifestyle medicine 
intervention for patients with chronic conditions reported improvements in total 
cholesterol, low-density lipoprotein cholesterol, blood glucose, body weight, physical 
activity level, fruit and vegetable intake, risk for myocardial infarction, risk for any 
cardiovascular disease event, self-reported unhealthy days, and qualitative survey data.111 
Other published studies demonstrate that inclusion of a pharmacist in the medical team of 
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a tertiary hospital significantly shorten length of stays, and lower both pharmacy and total 
hospital costs, while addition of a pharmacist to a pulmonologist practice improve asthma 
self-management.112,113 
 
Inclusion of pharmacists in primary care practices has also helped to achieve 
PCMH accreditation by increasing chronic care quality measures, as discussed in a recent 
publication.114 This was achieved through pharmacists’ recommendations on the use of 
angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker 
(ARB) medications to patients with concomitant diabetes mellitus and hypertension. 
Another outcome of this study is the positive recommendations acceptance rate. 
Physicians agreed with recommendations to initiate therapy in 54.7% of the patients, and 
therapy was started in 68.3% of those patients.114 The acceptance rate for pharmacists’ 
recommendations is even higher in a randomized control study conducted in 24 sites in 
Ontario. Specifically, physicians implemented or attempted to implement 72.3% of the 
recommendations. These results reflect that physicians are receptive to recommendations 
to resolve drug-related problems. In the latter study however, pharmacists’ interventions 
did not yield any significant changes in health care use or cost outcomes.115 
 
Finally, Chisholm-Burns (2010) and colleagues examined 298 studies in a 
systematic review and meta-analyses that examined the effects of pharmacists as team 
members on patient care. The meta-analyses found that HbA1c, LDL cholesterol, blood 
pressure, adverse drug events, medication adherence, patient knowledge, and quality of 
life, were all favorable towards pharmacists’ direct patient care over comparative services 
(p<0.05).  
 
Consistent with the PCMH principles to provide continuous patient-centered care, 
pharmacists are typically integrated in care teams for chronic diseases to enhance the 
quality and safety of health care. Impact of these efforts have been examined from a 
broad range of outcomes, from clinical, utilization and economic outcomes, as well as 
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physician acceptance rate for pharmacists interventions. Although some studies did not 
find significant changes in outcomes, the Asheville study demonstrated not only positive 
improvements for the patients, but that these outcomes are sustained over the long-term. 
These evidence, together with the comprehensive review by Chisholm-Burns, serve as 
strong support for the inclusion of pharmacists as key members of the health care team. 
Although this support exists in the literature, several challenges and barriers may impede 
pharmacists being fully integrated into primary care settings. Below is a discussion of 
several challenges and barriers regarding pharmacist involvement in collaborative care. 
1.2.4.3 Challenges and Barriers for Pharmacists in Collaborative Care 
Despite the changing landscape of primary care, many physicians may not have 
worked with pharmacists in such a direct manner and this can therefore lead to unique 
challenges.4,116 Foreseeing challenges and being preemptive in tackling the barriers in the 
integration of pharmacists in PCMH is vital to promote effective collaboration and to 
provide the best care to patients. 
 
First, due to the physician-led structure of PCMH, it may be easy to forget the 
inclusion of other health care practitioners including pharmacists.4 Many clinicians are 
also not familiar with pharmacists’ training and skills.23 Besides the need to educate 
physicians regarding the scope of clinical pharmacists’ responsibilities, there is also a 
need to cross-train and foster understanding among other team members to promote 
transparency and to improve transfer of information in integrated care. 
Acknowledgement of the pharmacists’ roles in PCMH should be supported at all levels 
and pharmacists must be proactive in demonstrating their value and interest to be part of 
the PCMH team.4 
 
Next, payment has been repeatedly discussed as a major barrier to the integration 
of pharmacists in MTM and collaborative care. To date, there is no consensus on a 
systematic payment model that adequately compensates clinical pharmacist services.4,23 
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Hence, calls for more outcomes studies related to pharmacist services should be 
encouraged with the aim to develop payment models for the services.4 One 
recommendation is to pay according to performance bonuses and care coordination.23 For 
small practices (one or two physicians), contracting clinical pharmacists for targeted 
patients is recommended as the inclusion of pharmacists in such a scenario may not be 
cost-effective.23 Besides payment issues, communication is of vital importance.  
 
Heather and colleagues (2015) have identified issues within the arena of 
pharmacist-physician communication. These include weakness of electronic 
communications and the absence of pharmacists onsite, all of which may lead to 
misunderstanding and defensiveness regarding recommendations.116 Surprisingly, 
although utilization of medical information technology and EMR is increasing, efforts to 
ensure that the system is working effectively for integrated care are still needed.4 
Additionally, it has been reported that community-based pharmacists typically do not 
have access to complete patient charts and have to depend on calling or faxing to gather 
relevant information, which interrupts conducive work flow and risks misinterpretation of 
information.23 Nevertheless, the EMR has been reported to successfully facilitate 
coordination in PCMH. This is demonstrated in a decentralized PCMH setting with 16 
offices and one pharmacist. In this PCMH, the pharmacist effectively reviews patient 
charts from a central office location through the EMR.114  
 
Overall, for a successful integration into the PCMH model, pharmacists should 
communicate regularly within and outside the pharmacy profession including state 
associations; advocate for efficient information technology and payment structures; be 
resourceful; and perform collaborative pharmacist services to generate trust for 
sustainable relationships. Standards and accreditations may provide guidelines, but the 
full potential of pharmacists cannot be achieved without addressing the issues and 
barriers pertaining to the roles of pharmacists in PCMHs.4 Rigorous assessments that 
detail the involvement of pharmacists in the team, decision making, care quality, and 
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clinical endpoints should be conducted to determine best practices for integration.23 
Despite the challenges, pharmacists are gradually gaining recognition for their expertise 
and competence, and eventually getting more acclimated to collaboration.117  
1.2.5 Federally Qualified Health Centers (FQHCs) 
With current advancements in the medical field, there is still disenfranchisement 
of access to primary care and a shortage of primary care providers, especially in low-
income areas, and among rural residents, ethnic minorities, and the uninsured.118 
Evidence has shown that access to primary care can help mitigate disparities in the health 
care system.119 Community Health Centers (CHCs) have provided high quality primary 
care to the underserved and have saved over $20 billion annually in health care system 
expenditures.118 CHCs typically serve low-income ethnic minorities, who are uninsured 
or are publicly-insured. Therefore, these centers serve as the bridge to provide primary 
care to this vulnerable population. CHCs that operate under specific federal standards are 
designated as federally qualified health centers (FQHCs).57,118,120  
 
FQHCs are “safety net” outpatient clinics enacted under Medicare in 1991 to 
provide primary care services in underserved urban and rural communities.121 They are 
mandated to serve all patients without regard to their ability to pay and a sliding fee scale 
is available for the uninsured.57,118,122 In addition to CHCs, public housing centers, 
outpatient health programs funded by the Indian Health Service, and programs serving 
migrants and the homeless are other examples of FQHCs facilities.121 FQHCs qualify for 
specific reimbursement systems under Medicare and Medicaid and funds are dispersed 
from the Health Resources and Services Administration (HRSA) through the Bureau of 
Primary Health Care.119,120,123 Federal government owned or sponsored primary care 
facilities such as CHCs are part of the government’s actions to address access to primary 
care.57 FQHCs are usually governed by a board of directors comprised of people who use 
the health center.122 Services provided include physician, nurse and dental services, as 
well as medications, diabetes self-management training, social services, mental health 
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services, preventive health screenings and women’s health services.121,123 
 
CHCs, specifically FQHCs are traditionally focused on cultural competence, team 
work and patient-centrism.119 Furthermore, a systematic review supported the value of 
multidisciplinary teams and community outreach in addressing disparities in chronic 
diseases.124 Therefore, FQHCs are in an optimal position to be developed as PCMHs and 
to focus on reducing health care disparities by providing access to quality primary 
interprofessional care.119,122 Advanced FQHCs with a PCMH model have also been 
associated with improved provision of preventative services and health outcomes.122 
Below is a description of FQHCs in central Texas, which serve as the site for this study. 
1.2.5.1 CommUnityCare in Travis County, Texas 
Health clinics were established in Travis County in 1970 to provide primary care, 
dental care and family planning for low-income individuals and the uninsured. In 2001, 
the CHCs received a federal grant which led to their qualification as FQHCs.125 In 2009, 
the network became a private, non-profit corporation under the name of 
CommUnityCare, with the majority of funding from Central Health (Travis County’s 
public entity that focuses on access to underserved communities) and the Federal Bureau 
of Primary Health Care, with additional funding from public and private grants.125,126 
 
As of 2014, CommUnityCare clinics are available at 23 locations in Travis 
County, serving more than 80,000 patients.127 Primary care, dental care, behavioral health 
and specialty services are provided to Travis County residents with low-income and no 
private insurance.128 CommUnityCare has incorporated the concept of PCMH in several 
of their health centers with team-based care that adheres to evidence-based medicine, 
patient and family empowerment, and participation.129 Travis County FQHC PCMHs 
involved pharmacists in their model of collaborative care for patients with chronic 
diseases, including diabetes. The next section provides a brief overview of the disease 
state of interest in this study: diabetes. 
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1.2.6 Diabetes Mellitus 
Diabetes mellitus is a chronic metabolic disease due to defects in the pancreas 
resulting in insufficient insulin production (insulin deficiency), or inability of the cells to 
respond to insulin (insulin resistance), or both.130–132 Consequently, glucose in the blood 
fails to be absorbed into the cells, leading to hyperglycemia. Symptoms of diabetes 
mellitus include frequent urination (polyuria), lethargy, weight loss, excessive thirst 
(polydipsia), and hunger (polyphagia).130,132 Chronic hyperglycemia is associated with 
long-term complications such as microvascular complications (retinopathy with potential 
loss of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of 
foot ulcers and amputations) and macrovascular complications (coronary artery disease, 
stroke, peripheral arterial disease).130 Besides that, diabetes patients have increased the 
risk of hypertension and dyslipidemia.7,130 
 
The etiology of diabetes remains unclear although it has been related to both 
genetic and environmental factors.131,132 The two main types of diabetes are Type I and 
Type II diabetes. Approximately 5-10% of diabetes patients are diagnosed with Type I or 
insulin-dependent diabetes, where the pancreas produces little or no insulin. The most 
common form of diabetes that affects 90-95% of diabetes patients is Type II or 
noninsulin-dependent diabetes, where the pancreas produces sufficient insulin but it is not 
efficiently utilized by the tissues. Type I diabetes is typically diagnosed in children or 
young adults while Type II diabetes is most commonly diagnosed in adults.130–132 Obesity, 
race, metabolic syndrome (hypertension and hyperlipidemia), age and family history have 
been associated with higher risks of developing Type II diabetes. Other less common 
types of diabetes include gestational diabetes, genetic defects of beta-cell function or 
insulin action, disease of the exocrine pancreas, and drug- or chemical-induced 
diabetes.130 
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1.2.6.1 Prevalence, Incidence, Morbidity, Mortality and Burden of Diabetes Mellitus 
According to the World Health Organization (WHO), the global prevalence of 
diabetes in 2014 was estimated to be 9% and diabetes was responsible for an estimated 
1.5 million deaths in 2012.5 The burden of the disease is predicted to increase in 
developing and developed countries worldwide.133 According to the data from Centers for 
Disease Control and Prevention (CDC), diabetes is becoming more prevalent in the US 
and number of Americans with diagnosed diabetes increased more than threefold from 
1980 to 2014.6 In 2014, the United States alone was estimated to have 29.1 million 
people with diabetes, which is equivalent to 9.3% of the U.S. population. Of this, 
approximately one-third is undiagnosed. Prevalence of diabetes is found to be the highest 
among those 65 years and older (11.2 million, 25.9%) and in men (15.5 million, 13.6%). 
Statistics from 2010 to 2012 report that American Indians have the highest percentage of 
diagnosed diabetes, followed by non-Hispanic blacks and Hispanics. For those under 20 
years of age, about 200,000 people have diagnosed diabetes, corresponding to about 
0.25% of the population in this age group.7 
 
Data from 2012 shows that there are 1.7 million new cases of new diabetes 
diagnoses among adults over 20 years of age, translating to 7.8 cases per 1000 people. 
Additionally, it is estimated that there are 86 million Americans with prediabetes.7 Boyle 
and colleagues (2010) have projected the prevalence of diabetes in the US to increase to 
25 – 28%, and the incidence of diabetes to increase to 15 cases per 1000 people by 
2050.134 
 
Because diabetes can affect many parts of the body, long-term complications from 
diabetes are major causes of morbidity and death.7,131 According to the most recent data 
from the CDC, hypoglycemia and hyperglycemic crises contributed to more than 450,000 
emergency room visits. Of all adult diabetes patients over 18 years old, 71% have high 
blood pressure and 65% have high LDL cholesterol. Hospitalization rates for heart attack 
and stroke are 1.8 and 1.5 times higher, respectively, among adults with diagnosed 
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diabetes as compared to those without. Microvascular complications are responsible for 
retinopathy in more than 30% of the diabetes population. These complications are also a 
primary cause in 44% of new cases of kidney failure, and 60% of non-traumatic lower-
limb amputations in people with diagnosed diabetes. Additionally, diabetes can also lead 
to nerve disease, non-alcoholic fatty liver disease, periodontal (gum) disease, hearing 
loss, erectile dysfunction, depression, and complications during pregnancy.7 
 
In terms of mortality, diabetes has been reported as the seventh leading cause of 
death in the US in 2010. Diabetes has been listed as the underlying cause of death and 
mentioned as a cause of death in 69,071 and 234,051 death certificates, respectively. The 
actual number may be higher as these figures may be underreported. In addition, earlier 
data estimated that rates of death from all causes were about 1.5 times higher among 
adults aged 18 years or older with diagnosed diabetes than among adults without 
diagnosed diabetes.7  
 
For the year 2012, the total cost of diabetes in the U.S. was estimated at $245 
billion. This is further divided into $176 billion in direct medical costs and $69 billion in 
reduced productivity. Hospital inpatient care accounts for the higher proportion in the 
total medical cost (43%), followed by prescription medications to treat the complications 
of diabetes (18%), antidiabetic agents and diabetes supplies (12%), physician visits (9%), 
and nursing/residential facility stays (8%). Along with this, the average medical 
expenditures for people with diagnosed diabetes was 2.3 times higher than those without 
diabetes.135  
 
This data, together, excluding costs of intangible pain and suffering, and those 
from undiagnosed diabetes, clearly underscores the disproportionate burden that diabetes 
imposes on society.135 Diabetes is a classic example of a disease that needs patient-
centered care, which may be achievable through a PCMH model.  
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1.2.6.2 Management of Diabetes Mellitus 
Diabetes is diagnosed based on the laboratory criteria of the amount of glucose in 
the blood, specifically when any one of the conditions below is met (Table 1.3):  
Table 1.3 Criteria for the diagnosis of diabetes 
Test criteria Threshold level Note 
HbA1c ≥ 6.5%  
Fasting plasma glucose 
(FPG) 
≥ 126 mg/dL 
(7.0mmol/L) 
Fasting is defined as no caloric 
intake for at least 8 hours 
Two-hour plasma glucose 
(2-h PG) during oral 




OGTT test should be performed 
using a glucose load containing the 
equivalent of 75g anhydrous glucose 
dissolved in water 
Random plasma glucose ≥ 200mg/dL 
(11.1mmol/L) 
In patients with classic symptoms of 
hyperglycemia or hyperglycemic 
crisis 
Source: Adapted from “Standards of medical care in diabetes 2014”, American Diabetes Association, 
Diabetes Care, 2014, page S15.  
 
Glycated hemoglobin A1c or commonly abbreviated as HbA1c is the objective 
measure for glycemic control and is the gold standard for monitoring diabetes over time. 
HbA1c reflects average plasma glucose levels over the previous 8 to 12 weeks. 
Management guidelines recommend HbA1c measurement every 3 months to determine if 
target control is met, especially for patients who do not meet therapy goals or had recent 
therapy changes.136,137 For patients who have stable glycemic control or who are meeting 
treatment goals, it is that they receive two HbA1c tests a year. Alternatively, testing with 
point of care (POC) devices allows for more convenience and more timely treatment 
adjustments.137 
 
The general target level of HbA1c in the US is less than 7%, although the target 
should be individualized according to the treatment regimen, complications risk, 
comorbidities, life expectancy and patient preferences.137,138 For example, diabetes 
patients with microalbuminuria (an indication of poor renal function) will have a lower 
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target range for the purpose of lowering the cardiovascular risk. In contrast, the target 
range for the elderly and patients with shorter life expectancy may be higher. 138 
 
Irrespective of the HbA1c target, evidence from the US139 and UK140 populations 
have showed that any reduction in HbA1c is significantly associated with reductions in 
risk of complications. The UK prospective diabetes study (UKDPS) specified that a 1% 
reduction in HbA1c is associated with reductions in the following: 21% reductions in risk 
for any end point related to diabetes (95% confidence interval 17% to 24%, p < 0.0001), 
21% for deaths related to diabetes (15% to 27%, p<0.0001), 14% for myocardial 
infarction (8% to 21%, p<0.0001), and 37% for microvascular complications (33% to 
41%, p<0.0001).140  
 
To achieve HbA1c reduction, diet changes, weight control and physical activities 
are necessary.132,137,141 Pharmacological invention is usually started for more severe 
patients upon diagnosis, or it may be added when lifestyle interventions fail to control the 
diabetes.141 Diabetes medications may include single or multiple oral medications (e.g., 
metformin, sulphonylureas, glitazones and acarbose) or insulin injections, or a 
combination of both.132,137,138,141 Insulin is usually the main agent for Type I diabetes 
patients, and commonly indicated for many patients with Type II diabetes due to the 
progressive nature of Type II diabetes.137 
 
Medications cannot be successful in managing glucose levels of the patient 
without management of caloric intake and weight. Details on carbohydrate counting, 
alcohol consumption, sodium intake, targets for weight loss should be provided to 
patients to assist in the control of this noncommunicable disease.137 These can be 
achieved through diabetes education, which is critical for diabetes management. 
Structured education programs during the diagnosis stage and subsequently, on a regular 
basis that is facilitated by group education on self-care directed by skilled professionals is 
highly recommended.138  
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Throughout the years, diabetes care has shifted from hospitals to primary care and 
it is usually first diagnosed and managed by primary care physicians.142,143 For that 
reason, diabetologic education and self-care as tools that empower diabetes patients with 
the knowledge and support to manage their condition should be provided in primary, 
outpatient and community care settings, with the ultimate objective to prevent or slow the 
development of complications.137,143 Diabetes education should foster patient participation 
based on patient-centeredness, an approach that is also emphasized in PCMH. To 
elaborate, diabetes education and support may include dietetic information, 
pharmacological treatment, physical exercise, complications, self-care of feet, 
psychosocial issue management and self-analysis for insulin dose adjustment.137,138 
Numerous studies have reported that these structures help to improve clinical outcomes, 
quality of life and overall costs.137 
 
Because the care for diabetes patients is multifaceted, a team-based approach that 
may include physicians, nurse practitioners, physician’s assistants, dietitians, 
pharmacists, and mental health professionals with expertise in diabetes is important.137,138 
Pharmacists, are an important asset to enhance medication adherence, and to provide 
related diabetes education. Diabetes related outcomes from team-based care with 
pharmacist integration are discussed in the following section. 
1.2.6.3 Diabetes Outcomes with Pharmacist in Integrated Care 
 The Asheville project in North Carolina is the landmark study that provided 
evidence for the contributions of pharmacists in the management of diabetes. Pharmacists 
based in community pharmacies were certified diabetes educators who provided long-
term follow-up, clinical assessment, goal setting, monitoring, and collaborative drug 
therapy management with physicians. The pharmaceutical care services conducted 
throughout the 5-year study resulted in a reduction of mean HbA1c and lipid levels at all 
follow-ups, with more than 50% of patients demonstrating improvement at each 
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measurement. The number of patients with optimal A1c values (<7%) also increased at 
each follow-up. Besides that, adherence to self-care (e.g., foot exams and self-monitoring 
of blood glucose) improved. Regarding economic outcomes, costs shifted from inpatient 
and outpatient physician services to prescriptions, which increased significantly at every 
follow-up. Total mean direct medical costs decreased by $1,200 to $1,872 per patient per 
year compared with the baseline. Days of sick time decreased every year (1997–2001) for 
one employer group, with estimated increases in productivity estimated at $18,000 
annually.144 
 
 Numerous studies have reported similar outcomes since the Asheville project, 
particularly with clinical outcomes (e.g., HbA1c, LDL and blood pressure).33,105,145,146 For 
example, a pharmacist-led clinic in Pittsburg, Pennsylvania improved outcomes in 
HbA1c, body mass index (BMI), LDL, HDL, total cholesterol, triglycerides and blood 
pressure.107 In another study in a VA setting, pharmacist-led group appointments targeted 
for diabetes patients with depression revealed a greater change in the proportion of 
participants achieving HbA1c <7% in the treatment arm than with standard care (29.6% 
vs 11.9%), with odds ratio 3.6 (95% CI 1.1 to 12.3).147 
 
 A 2014 review of collaborative pharmacy practice demonstrated that in addition 
to improvement in clinical measures, pharmacists practicing in a variety of outpatient 
environments can also improve adherence to standards recommended by the American 
Diabetes Association (ADA). The ADA guidelines include yearly monofilament exams, 
dilated eye exams, microalbumin screening and flu/pneumococcal vaccines.146 Likewise, 
one study with the specific intervention of pharmacist-provided diabetes assessment 
services one week prior to physician appointment (n=314) in a university-based family 
medical center found significantly higher proportion of each standard completed 
(glycosylated hemoglobin, lipids, foot exam, eye referral, pneumococcal and influenza 




 Conversely, another VA health care system that integrated pharmacists in 196 
primary care clinics found no significant association between pharmacist presence and 
oral hypoglycemic agent adherence. The authors suggested reexamining the exact roles of 
pharmacists and a better understanding of their roles to maximize this resource to 
improve patient outcomes.149 
 
Published PCMH studies have also shown positive health care utilization 
outcomes on chronic diseases. Implementation of PCMH was associated with savings in 
ED utilization (23% less than projected), outpatient care (25% less than projected), and 
pharmacy (11% less than projected) in a community setting.150 One other innovative 
collaborative study with pharmacists integrated into the team, reported a reduction in all-
cause admissions, readmissions and cost savings for health plan members with 
diabetes.151 A previous study conducted to evaluate the changes in diabetes-related 
hospitalization and ED visits for patients in CommUnityCare found a significant increase 
of eight hospitalizations (8 visits per 220 patients, mean = 0.036, SD = 0.284) for patients 
in the control group while the intervention group had a decrease of one hospitalization (-1 
visit per 220 patients, mean = - 0.005, SD = 0.278). Although the change in ED visits was 
not significant in this study, patients in the control group had a higher increase of 16 ED 
visits (16 visits per 220 patients, mean = 0.073, SD = 0.584), as compared to the 
intervention group which had an increase of 4 ED visits (4 visits per 220 patients, mean = 
0.018, SD = 0.641).152 Overall, the literature that compared the impact of PCMH 
pharmacists in diabetes focused on clinical outcomes, and there is a dearth of publications 
that document utilization outcomes. 
1.2.6.4 Cost Effectiveness of Integrated Models  
 Apart from improving clinical outcomes, lowering of health care costs is also an 
important aim of PCMHs.27 Similar to other outcomes, the impact of pharmacists on 
economic outcomes is also equivocal. According to the latest report by Patient-Centered 
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Primary Care Collaborative (PCPCC), more than half of the studies (17 out of 28 studies) 
published between September 2013 and November 2014 indicate improvement in costs 
with primary care PCMH interventions.153 
 
Four published studies highlighted improved outcomes and cost savings while 
another two studies found no overall change in total costs. The first study, which was 
based in Ohio, compared the direct participation of a pharmacist on a patient care team 
with a control team. Hospital stays, pharmacy and total hospital costs were all lower at 
the end of this 9-month study.112 Similarly, another study found that MTM interventions 
lowered the odds of hospitalization and hospitalization costs for patients with diabetes or 
heart failure. However, there was no improvement in patient satisfaction and health-
related quality of life.93 Lower median per member per month health care costs have been 
observed in an MTM system developed over 13 years in an integrated health system in 
Minnesota, when compared to usual care sites.154 One study attempted to assess health 
and cost outcomes over a 20-year period. The simulated controlled trial data suggests that 
PCMH can cost-effectively reduce complications and mortality from diabetes ($7898 per 
quality-adjusted life year).155  
 
Two PCMH studies found no overall savings in costs. Group Health’s pilot 
PCMH clinics in Seattle reported that primary care costs were significantly higher and 
ED visits were also significantly lower, which resulted in no significant differences in 
overall costs after 12 months of PCMH implementation.79 In contrast, another publication 
that examined Group Health’s outcomes in diabetes patients reported increases in ED 
visits.156 In a separate multi-payer medical home pilot implementation, neither hospital, 
ED, or ambulatory care services nor total utilization costs were reduced over 3 years.157 
 
Ackroyd and Wexler (2014) have discussed that evaluating costs in diabetes is 
challenging as savings may only be observed over a long term (e.g. multiple years). It 
should also be noted that the discussion on cost-effectiveness is not meaningful without 
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engaging payers and the corresponding payment reforms for medical homes. Therefore, 
payments tailored to PCMH structures which provide incentives for providers to 
encourage implementation of the model is an important component of the medical home 
model.158 Lastly, although the cost-effectiveness of PCMH for the management of 
diabetes is not well understood, it has been suggested that interventions are typically most 
effective, and hence most cost-effective for diabetes patients with the poorest control at 
baseline and for low-income populations.27,159  
1.2.7 Diabetes Mellitus in Underserved Populations 
It is well documented that the burden of diabetes is higher among minorities and 
lower-income groups in the US, and this burden in this population has been associated 
with higher prevalence, worse control and higher complication rates.8,9 Racial or ethnic 
minority groups that include African Americans, Hispanics, Asians, Native Hawaiians 
and Other Pacific Islanders, American Indians and Alaska Natives are more likely than 
non-Hispanic Whites to be poor and have lower education. These have been linked to 
cultural and language barriers, uninsured status and poor access to care. The disparities in 
access and quality of care subsequently lead to higher risk of diabetes complications.10,11 
 
Asian Americans have a 1.2 times higher risk of diagnosed diabetes as compared 
to non-Hispanic Whites while Hispanics and non-Hispanic Blacks both have a 1.7 times 
higher risk. All other minorities also have a higher percentage of diagnosed diabetes as 
compared to non-Hispanic Whites (Figure 1.1).7 It is also common for these populations 
of patients to seek care in the later stage of the disease, therefore increasing the cost and 
burden to the health care system.10 A published review found that children who are 
uninsured, non-white and from lower-income families are less likely to have medical 
homes.69 There is a national urgency to reduce disparities and improve the quality of care 
in the management of diabetes among vulnerable populations.11 
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Figure 1.1 Racial and ethnic differences in diagnosed diabetes among people aged 20 
years or older (2010-2012) 
 
Source: Adapted from “National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the 
United States, 2014”, Centers for Disease Control and Prevention, 2014, page 2. 
 
Several initiatives have been developed to improve care for underserved 
populations.160 One of the widely implemented measures is the integration of health care 
professionals like nurses, medical assistants and pharmacists with certified diabetes 
education training in primary care clinics. These efforts have produced positive outcomes 
in patient empowerment, HbA1c, lipid levels, blood pressure, diabetes related 
examinations (e.g., eye and foot examinations) and smoking cessation.8,15,160,161 Many of 
these initiatives share similarities of having multidisciplinary teams in providing diabetes 
care.10,15,160 Trained pharmacists have been valuable in some rural communities with 
limited physicians. In these areas, patients can receive care without having to travel for 
health-related education and services.56 
 
There are many federal initiatives to diminish health care disparities, particularly 
in underserved populations with diabetes. These are typically done through CHCs or 
FQHCs that predominantly serve the needy.121 Besides that, the Healthy People 2010 
stated the aim to strengthen safety nets by increasing the number of CHCs in the US.162 
Other entities like the American Diabetes Association (ADA) has advocated for more 
diabetes research, treatment, education, and prevention in minority population.9 There are 
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various mechanisms by different stakeholders to remedy the disproportionate burden of 
diabetes among underserved populations. Despite that, the impact of these efforts, as well 
as national policies on health status of low-income minorities need more examination and 
effective measures identified should be disseminated better.8 
1.2.7.1 Integrated Care and Health Outcomes in Underserved Populations  
Health care providers, more so the provision of patient-centered care through 
comprehensive team-based approaches hold the key in overcoming the disparities in 
underserved populations.9 PCMHs have been increasingly used as a strategy to tackle this 
issue in underserved populations. There are published studies that examine PCMH 
implementation on health outcomes of underserved populations like Alaska Natives, 
minorities, homeless persons, and uninsured diabetes patients. Several PCMHs have 
pharmacists on the team and these studies are discussed below. 
 
One PCMH that mainly serves Alaska Natives has been integrating PCMH 
components since 1999. They report decreases in hospitalizations that are attributed to 
improved accessibility to the empaneled care teams.163 In another study, the same team 
reported overall positive findings on diabetes outcomes after implementing their PCMH 
and sustaining it for over 14 years. Significant changes include increases in rates of new 
Type II DM diagnoses and decreases in the number of ED visits. However, there are non-
significant results for: increases in rates of HbA1c screening, increases in percent with 
average HbA1c <7%, and decreases in the number of inpatient days. Despite the varying 
strength of evidence, data from the time series analysis of this study suggests that positive 
outcomes from PCMH interventions are sustainable over long periods of time.12 
 
Although a full PCMH structure may not have been implemented, other studies 
have focused on improving diabetes outcomes in underserved populations. One study 
applied a comprehensive systems-based disease management process including a diabetes 
registry and an EMR in a community of minority and homeless persons. This study found 
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significant improvement in quality indicators (percentage of patients having: HbA1c 
measured, HbA1c <7%, LDL measured annually, LDL <100mg/dL, retinopathy 
screening, microalbumin test), and suggested that the interventions helped reduce 
disparities between vulnerable and Caucasian populations.13 
 
Regarding the roles of pharmacists in diabetes management of high-risk 
populations, the American Pharmacists Association (APhA) Foundation has explicitly 
supported the engagement of pharmacists as integral members of health care teams in 
populations disproportionately affected by diabetes. Project IMPACT, a multisite 
observational study was designed specifically to examine the effect of pharmacists 
integrated to patient-centered, interdisciplinary health care teams, providing customized 
diabetes education and medication consultations to underserved patients. The pre-post 
comparison study (n = 1836) conducted in 25 communities across 17 states reported a 
significant and clinically relevant decrease in mean HbA1c levels (-0.8%, p < 0.001). 
Other clinical outcomes decreased significantly (p < 0.001) as compared to the baseline 
but not by clinically relevant amounts (LDL, −7.1 mg/dL; triglycerides, −23.7 mg/dL; 
and total cholesterol, −8.8 mg/dL). The mean increase in HDL (+0.6 mg/dL) was not 
statistically significant or clinically relevant. Additionally, 51.7% of 453 patients with 
uncontrolled diabetes during the baseline study received eye examinations, 72.0% of 271 
patients received foot examinations, 41.7% of 307 patients received influenza 
vaccinations, and 9.3% of 270 patients quit smoking during the project.15 
 
Similar to the IMPACT study, a study based in California compared clinical 
outcomes of uninsured or underinsured diabetes patients between patients receiving 
clinical pharmacists (n=222) services and that of usual care (n=262). Comprehensive 
pharmacy services for vulnerable populations with medical homes in local safety net 
clinics observed HbA1c levels reduced by 1.38% relative to usual care, increasing the 
likelihood of achieving an HbA1c <7% by 3-fold (p<0.001 for both estimates).16 Another 
study described integration of collaborative MTM into a safety net PCMH as a valuable 
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intervention for homeless patients. This PCMH targets primarily mental health problems 
and has a pharmacist on the team. The provider acceptance rate for recommendations of 
identified medication-related problems was high (89%).103 
 
Overall, the PCMH approach with pharmacists as essential members has been 
generating promising results for underserved patients with diabetes. Since much of the 
economic burden of diabetes is related to its complications, such as blindness, 
amputation, kidney failure, heart attack, and stroke, the value of these interventions in the 
management of diabetes in underserved populations with higher risks and burden is even 
more critical.9 With that, the paucity of research targeting underserved communities 
should be addressed and studies that focus on improving the outcomes should be 
encouraged.90 
1.2.7.2 Burden of Diabetes Mellitus in Texas and Travis County, and Need for PCMH 
According to the latest data from CDC, the age adjusted rate for diagnosed 
diabetes is 10.9% and the rate of new cases is 9.8 per 1000 for the state of Texas in 
2013.164 The prevalence of diabetes in Texas is estimated to have increased by more than 
50% in 10 years, from 2000 to 2010. In 2010, diabetes was among the top ten leading 
causes of death in Texas, with a mortality rate of 21.7 deaths per 100,000 persons. 
Regarding hospitalizations, diabetes was the principle reason or was a coexisting 
condition in 20% of total hospitalizations in Texas, accounting for 27% of total charges 
for all hospital stays. All of which indicates a high burden of the disease.165  
 
Specifically for Travis County, diabetes prevalence was estimated at 9.3% in 
2013.166 Austin is frequently named as one of the fittest cities in the US but disparities are 
continuously reported for minorities. Death rates and prevalence for diabetes, among 
other diseases, are persistently higher for African American and Hispanic populations.167 
Overall management of diabetes in Texas is reported to be poorer than the US average, 
with a higher percentage of patients with uncontrolled HbA1c, LDL, and blood pressure, 
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and lower rates for HbA1c testing, eye exam, LDL screening, and nephropathy 
management as compared to the national average.165 
 
There are many factors that could explain the high burden of diabetes in Austin 
and in Texas. First, African Americans and Hispanics or Latinos have higher risks for 
diabetes, are twice likely to die from diabetes, and are more likely to be obese when 
compared to whites. The two race groups together, comprise approximately half of the 
total population in Texas. In Texas, African Americans have the highest prevalence of 
diabetes as compared to other race groups and the Hispanic population is increasing.165,168 
Moreover, there are associations between higher prevalence of diabetes with lower 
education and household income levels. In Texas, there are a significantly higher 
proportion of adults who did not graduate from high school (13.6%), as compared to the 
US population (10.2%), which may contribute to the differences in diabetes prevalence.165 
 
It is apparent that the high burden of diabetes and health inequities due to the 
social determinants of health need urgent attention. The Austin/Travis County published 
a recent report that cited the issue of health inequities and emphasized the need for 
programs that empower patients and eliminate barriers to access care.167 Provision of high 
quality primary care via community health centers and PCMHs is a promising strategy 
that may remedy the disparities issue.119 Since 2011, support for PCMH for underserved 
population was shown in Texas when the Texas Health and Human Services Commission 
(HHSC) encouraged managed care organizations to develop incentive programs for the 
providers who implement PCMH for Medicaid patients.169 FQHCs in particular, can be 
the pioneer in incorporating the PCMH model and demonstrating the effective delivery of 
primary care in underserved patient populations by improving access to care, with the 
ultimate goal of reducing and even eliminating health care disparities.119 
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1.2.8 Study Rationale 
Although inconclusive, the literature has shown that the impact of integrated care 
and PCMH on health outcomes has been positive. This suggests that improved models 
and stronger evidence are needed to support its implementation in the long term. Even 
though other health care practitioners such as nurses and medical assistants can provide 
diabetes-specific education, pharmacists are specifically trained in the management of 
medications, and therefore have a unique position in team-based care.  
 
Furthermore, pharmacists have practice locations in nearly every community 
throughout the country, rendering them highly accessible. Thus, pharmacists are an ideal 
provider to deliver needed health care services, especially medication management, to 
underserved populations.15 Pharmacists have been gaining recognition in the provision of 
MTM and clinical services. The growing trust from physicians, other health care 
providers and society is also reflected with the increasing collaborative practice 
agreements across the country.23 Specifically, for the state of Texas collaborative drug 
therapy management protocol, pharmacists can initiate, modify or continue drug 
therapy.152  
 
The high burden of diabetes, which is even more pronounced in underserved 
populations, calls for more structured initiatives, such as PCMHs, to overcome this 
debilitating and resource intense disease state. Most studies involving pharmacist-
integrated PCMH with a focus on diabetes management in underserved populations 
compared clinical outcomes such as HbA1c and LDL, while few studies described the 
integration and implementation of clinical pharmacist services in PCMHs. 
 
The recent CommUnityCare (FQHCs in Travis County) PCMH transformation 
and integration of clinical pharmacists into PCMH teams provide an opportunity to 
investigate these research questions. The description of the PCMH structure and 
implementation methods may provide valuable information for future integration of 
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pharmacists into PCMHs and ACOs. Finally, this study may provide more evidence of 
the value of pharmacists in primary care settings that serve diabetes patients. 
1.2.9 Study Aims 
To describe the integration of pharmacy services in FQHC PCMHs. 
1.2.10 Objectives 
The specific objectives of this study are listed as below: 
1. To describe and compare the integration of clinical pharmacist services in 
the PCMH and usual care FQHCs, according to the following themes:  
a. PCMH structure and workflow 
b. Roles of pharmacist 
c. Benefits and challenges of PCMH structure 
2. To describe the implementation of clinical pharmacist services in PCMH 
FQHCs, according to the Joint Principles of PCMH: 
a. Personal physician  
b. Physician directed medical practice 
c. Whole person orientation  
d. Care is coordinated and/or integrated  
e. Quality and safety 
f. Enhanced access 
g. Payment  
3. To qualitatively compare clinical pharmacy services provision between all 
FQHCs, more specifically on: 
a. Health care professionals involved 
b. Workflow and interprofessional collaborations 
c. Referral and screening of diabetes patients 
d. Implementation of clinical pharmacist services 
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CHAPTER 2: METHODOLOGY 
2.1 STUDY DESIGN OVERVIEW 
The objectives of this study, which are to describe integration and implementation 
of clinical pharmacy services provision in FQHC PCMHs were addressed by conducting 
semi-structured interviews with four clinical pharmacists in Travis County FQHCs. Three 
FQHCs with the PCMH model (PCMH group) have pharmacist services provided on the 
same day of physician visit (co-visit), while one FQHC with usual care (UC group) has 
pharmacist services provided on separate days, independent of a physician visit. 
2.2 INSTITUTIONAL REVIEW BOARD APPROVAL 
The Institutional Review Board (IRB) application was submitted to The 
University of Texas at Austin IRB. Waivers were granted as information required in this 
research was deemed as non-human subjects. 
2.3 STUDY DESIGN 
Semi-structured one-on-one qualitative interviews were employed to address the 
study objectives. 
2.4 STUDY INSTRUMENT  
A semi-structured interview guide was developed to compare pharmacist-
integration in PCMH and usual care models. Semi-structured interviews are useful tools 
to elicit detailed descriptions of individual experiences and behavior, with the advantages 
of immediate clarification of ambiguities and probing for further information based on 
participant responses.170–172 The questions were designed to investigate the 
implementation of clinical pharmacy services from the experiences of interviewees 
providing the services. The interview guide included open-ended questions with the 
following broad themes: 1) PCMH structure and workflow, 2) roles of pharmacists, and 
3) benefits and challenges of PCMH structure. The broad questions are followed-up with 
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more specific questions on health care professionals involved, pharmacist-physician 
collaboration, patient selection criteria, clinical pharmacist service provision, 
documentation, and communication, when appropriate. 
 
The purpose of PCMH structure and workflow questions were to better 
understand: 1) clinical pharmacist implementation approaches adopted by the study sites, 
2) referral and screening criteria, 3) patient load, and 4) average patient visit duration. 
The roles of pharmacists questions included the extent and types of clinical pharmacy 
services provided during co-visits and pharmacist-only visits. The benefits and 
challenges of PCMH structure questions were included to explore the pharmacists’ 
opinions and experiences with the current system. Understanding the exact roles of 
pharmacists and comparing the differences in service provision may serve as guidance for 
other FQHCs or other settings who are interested in integrating pharmacists into PCMHs.  
2.5 STUDY SITES AND PARTICIPANTS 
The study sites were four FQHCs in Austin, Texas, named CommUnityCare. 
Currently, there are 23 FQHCs in central Texas, including 12 clinics that include 
pharmacists as an integral part of the health care team. Clinical pharmacists have worked 
under a collaborative practice agreement with internal medicine physicians since 2005. 
Under the current collaborative practice agreement, pharmacists have prescriptive 
authority to initiate and/or adjust diabetes medications, as well as order labs.173  
 
Since early 2013, three of the FQHCs (PCMH1, PCMH2, PCMH3) instituted a 
PCMH model with co-visits, where clinical pharmacist services are provided on the same 
day as physician visits, with emphasis on interprofessional collaboration. In addition to 
co-visits in the PCMH FQHCs, pharmacist-only visits were also provided on a scheduled 
basis, irrespective of when the patient sees the physician. Similarly, in the usual care 
clinic (UC), pharmacist-only services are also provided irrespective of physician visits. 
Notably, the usual care clinic uses a disease therapy management usual care model and 
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does not employ PCMH co-visits. The pharmacist on staff only sees patients with chronic 
illnesses who are referred by their physician. Patient characteristics (i.e., insurance 
coverage, demographics) were similar among all four clinics.173 Purposive sampling was 
used to recruit the study sample. The study participants are four clinical pharmacists 
employed by the FQHCs and who agreed to participate in the study. 
2.6 DATA COLLECTION AND ANALYSIS 
Four face-to-face, one-on-one semi-structured interview sessions were arranged 
and conducted with clinical pharmacists working in three PCMH FQHCs and one usual 
care FQHC. The interviews were audio recorded with notetaking by the same interviewer 
to reduce bias. Qualitative content analysis was conducted independently by two 
researchers to examine and compare the interview content. Data were categorized and 
agreement was achieved through discussions. 
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CHAPTER 3: RESULTS 
3.1 CHAPTER OVERVIEW 
This chapter presents the results of this study in the order of the interview content 
themes. The integration of pharmacy services is described and compared among the study 
sites. Table 3.1 summarizes the main findings from the interviews. 
3.2 SEMI-STRUCTURED INTERVIEWS WITH CLINICAL PHARMACISTS 
On average, each interview session lasted 45 to 60 minutes. The interview content 
based on the recorded sessions and notes taken during the interviews are presented below. 
Specifically, the results are presented according to the structure and workflow of the 
PCMHs, roles of pharmacists, and benefits and challenges identified from the study sites. 
3.3 PCMH STRUCTURE AND PHARMACIST WORKFLOW IN COMMUNITYCARE 
Health care professionals involved in PCMH 
The types of health care professionals are similar for the study clinics in 
CommUnityCare although the number of health care staff varies by the size of the clinic. 
Medical assistants, nurse practitioners, nurses and behavioral health counselors are 
available in all four clinics. Dietitians and social workers are onsite in some locations, but 
are available to other clinics via referral. The number of physicians ranged from two to 
five in the study locations and each physician typically has two support staff. Clinics 
PCMH2 and UC have one clinical pharmacist, while clinics PCMH1 and PCMH3 that are 
relatively larger and serve more patients have two clinical pharmacists. The estimated 
number of providers (health care professionals that can prescribe: physicians, nurse 






Workflow and interprofessional collaborations 
The PCMH workflow involves all healthcare practitioners mentioned above. In 
the PCMH clinics, medical assistants or nurses take patients’ vitals and other important 
notes electronically prior to physician consultations. The following terms in this study are 
illustrated in Figure 3.1 and defined as below: 
• Co-visits: Clinical pharmacist services provided on the same day as 
physician visit (either before or after), with emphasis on interprofessional 
collaboration. Co-visits are available in three study clinics (PCMH 
clinics). 
• Pharmacist-only visits: “Non co-visit” clinical pharmacist services 
provided on scheduled basis, irrespective of physician visits (typically on 
different days). Pharmacist-only visits are available in all four study 
clinics (PCMH and UC clinics). 




On co-visit days, the pharmacists may see the patients before or after physician 
consultation, depending on the physician’s schedule. However, the pharmacists in the 
PCMH clinics reported that most pharmacist visits are conducted before the physician 
visits. The pharmacists also report this as the preferred workflow because it allows the 
pharmacists to review the blood glucose readings that physicians typically have limited 
time to review. When necessary, dietitians and social workers may also see the patient on 
the same visit day. The main distinction regarding workflow between PCMH and UC 
clinics is that there are no co-visits in UC, as patients are seen by physicians and 
pharmacists on separate days. 
 
Clinical pharmacy services for both PCMH and UC clinics are provided 
according to MTM components and evidence-based medicine, both of which are guided 
by the collaborative practice agreement. Pharmacists manage the patient by reviewing the 
medical plan, assessing efficacy, safety and adherence to medications, providing disease 
state education, and working with the patient to set self-management goals. Pharmacists 
then document and communicate plans to the prescriber. This entire process is similar for 
both co-visits (PCMH) and pharmacist-only visits (PCMH and usual care), and it may 
occur before or after the physician appointment. Thus, interprofessional collaborations 
are similar. 
 
Referral and screening of diabetes patients 
Pharmacy services are provided to diabetes patients who are identified through 
referral or screening. In all four clinics, referrals vary according to physicians and clinics. 
Pharmacists typically receive referrals for patients with: uncontrolled diabetes; controlled 
diabetes, but who may need additional education; or those who are newly diagnosed. 
Pharmacists may also receive referrals from medical assistants and nurse practitioners. In 
addition to referrals, pharmacists in two of the PCMH clinics (PCMH1, PCMH2) 
proactively screen for diabetes patients who may benefit from pharmacist services. 
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Among the screening criteria are: recent hospitalization, patients who may need dosage 
adjustment (e.g. due to change in renal function), and needed therapy (e.g. statin, ACE 
inhibitor). Meanwhile, in the usual care FQHC, pharmacists do not proactively screen for 
patients: they utilize the referral mechanism for patient visits.  
 
Implementation of clinical pharmacist services 
Implementation of co-visits is similar among the three PCMH clinics with each 
employing fixed co-visit days with open scheduling. Specifically, co-visits are scheduled 
on two days each week for PCMH1, one day each week for PCMH2, and two mornings 
each week for PCMH3. The number of patients seen on a co-visit day is highly dependent 
on the physician’s schedule and may range from 0 to 6 for a co-visit session in the 
morning, or up to 15 patients per co-visit day. The duration of co-visits ranges from 5 to 
20 minutes.  
 
For pharmacist-only visits (see Figure 3.1), a scheduling system for clinical 
pharmacist services in all four clinics allows for up to 12 patient appointments per day, 
with 30-minute intervals for each appointment. The actual number of patients seen 
however, may range from 0 to 12 on each pharmacist-only visit day, depending on the 
number of scheduled pharmacist appointments and patient attendance. For pharmacist-
only visits, subsequent patient appointments are typically every four weeks, with 
exceptions for more urgent cases (e.g. patients who need more frequent insulin titration) 
where the appointment interval may occur every 2 weeks. For patients who achieve stable 
control of their diabetes, the follow-up interval for maintenance pharmacist appointments 
is usually every 3 months, or as needed. While each pharmacist appointment is scheduled 
for a maximum of 30 minutes, the pharmacists interviewed reported to have consultations 
lasting from 5 to 30 minutes.  
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Table 3.1 Provision of pharmacy services integrated in PCMH and usual care clinics 
Description PCMH1 PCMH2 PCMH3 UC 
Number of full time 
pharmacists 
2  
(+ 1 part time) 1 2 1 
Number of co-visit 
days/week 2 1 2 half days NA 
Average co-visit 
duration 
10 – 15 
minutes 
5 – 20 
minutes 
15 – 20 
minutes NA 
Average pharmacist-
only visit duration 5 – 15 minutes 
20 – 30 
minutes 30 minutes 




Usually every 4 weeks 









Typically face-to-face interaction 
Telephone visits for unique cases 
Pharmacist screen for 
patients Yes Yes No No 




9 4 7 5 
Number of diabetes 
patients* 1500 500 1200 1200 
*Estimated number of diabetes patients in 2014 
 
Documentation and communication 
Documentation is electronic and all interventions and notes are made in the 
electronic medical record (EMR). However, communication with the prescriber is mainly 
through face-to-face interactions during co-visits. The clinical pharmacists usually 
provide services and interventions independently according to the collaborative practice 
agreement and inform the prescribers about the changes made. The pharmacists 
interviewed noted that the physicians are generally receptive and suggestions are 
commonly accepted. Similarly, clinical pharmacy services are provided through face-to-
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face interactions with patients. Telephone interventions are less often utilized and only 
employed for specific cases, such as to follow-up on home blood glucose readings and 
for patients who need frequent insulin titrations. 
3.4 ROLES OF PHARMACISTS ACCORDING TO THE COLLABORATIVE PRACTICE 
AGREEMENT 
Services provided by the clinical pharmacists during co-visits and pharmacist-
only visits are guided by the collaborative practice agreement, which is the same for all 
clinics. According to the agreement, clinical pharmacists are authorized to prescribe 
and/or titrate medications, order and interpret laboratory results, order and administer 
vaccinations, provide disease state education, perform physical assessments, document 
interventions, and make referrals to other healthcare teams (e.g. dietitians, behavioral 
health counselors and social workers). These services are available for a number of 
disease states, including diabetes mellitus, as stated in the agreement. Apart from that, 
services integral to MTM such as medication reconciliation, adherence assessment and 
goal setting are also provided. Patients are also educated on basic lifestyle modifications 
such as exercise and diet. Additionally, some pharmacists take patient vitals during 
pharmacist-only visits.  
 
When comparing the types of clinical pharmacy services provided during co-visits 
and pharmacist-only visits, the pharmacists in the PCMH clinics reported that the types of 
patient education and services are generally similar, although pharmacist-only visits are 
usually more comprehensive. The pharmacists mentioned that co-visit sessions are often 
optimized for physician visits by focusing on specific issues, and pharmacists reinforce 
patient education and other issues during a subsequent pharmacist-only visit. However, 
for one clinic (PCMH2) with relatively new pharmacist-physician collaborations, the 
pharmacist provides recommendations to the physician on medications and dosage 
adjustments during co-visits. Pharmacists in other clinics, where pharmacist-physician 
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collaborations have been more strongly established, utilize their prescribing and titration 
privileges (outlined in the collaborative practice agreement) during co-visits. 
3.5 BENEFITS AND CHALLENGES OF THE CURRENT STRUCTURE 
Benefits of current PCMH structure 
Upon interviewing the pharmacists to compare their previous working experience 
prior to their role in PCMHs, all pharmacists commented that co-visits allow for more 
collaboration and more efficient communication with physicians. One pharmacist 
emphasized that in addition to managing the disease condition, pharmacists, being the 
medication experts, also help in managing the safety component of medication use (e.g. 
use of metformin in patients who are reaching serum creatinine thresholds) for the 
medical team. In addition to enhanced team work, pharmacists are appreciated for 
providing: detailed medication reconciliation, adherence assessment and 
recommendations to resolve medication-related problems among diabetes patients. 
Regarding appointment scheduling arrangements for clinical pharmacists, 
CommUnityCare utilizes an open schedule (a system that accommodates any patient that 
requires a same-day visit, regardless of a prior appointment) on co-visit days, which 
allows for patients to receive care when needed. The current structure also allows more 
convenience and flexibility for patients to see more health care providers on the same 
day, which is especially helpful for patients that have transportation challenges.  
 
Challenges of current PCMH structure 
Despite the advantages of an open schedule for co-visits, pharmacists commented 
that reserving co-visit days may not be efficient, particularly when they remain unused 
because no diabetes patients were scheduled for those slots. Therefore an open schedule 
may not be the most efficient way to optimize clinical pharmacists’ time. In contrast, the 
opposite occurs in clinics with more providers and fewer pharmacists. In a larger clinic 
(PCMH1) with higher demand for pharmacy services, the number of available 
pharmacists may not be sufficient to meet the needs of all patients. Consequently, 
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pharmacists can only see patients selectively, such as patients who are more severe or 
have more complications. In addition, there are some challenges associated with the 
physicians as indicated by one pharmacist; some providers believe that pharmacists 
should see only uncontrolled patients. One pharmacist also mentioned that the current 
number of social workers and the scope of their services are limited, particularly in 
clinics that serve primarily underserved populations. Lastly, from the pharmacists’ 
experiences, the barriers associated with diabetes patients in the FQHCs include the lack 
of education regarding the disease state, poor understanding of diabetes management, 






CHAPTER 4: DISCUSSION 
4.1 CHAPTER OVERVIEW 
This chapter discusses the findings of this study by comparing pharmacist 
integration to available literature. The implementation of pharmacist services according 
to the principles of PCMH is also highlighted (see also Table 3.2 for a summary). 
4.2 INTEGRATION OF PHARMACY SERVICES 
The approach engaged by FQHCs in this study to integrate pharmacists is unique 
to CommUnityCare clinics. Interestingly, even when the clinics are under the same 
management, implementation is slightly different among the clinics. These variations 
reflect the adoption of the principles of PCMHs being physician-directed and adapting 
to meet the specific needs of the patients and clinic. 
4.3 PCMH STRUCTURE AND PHARMACIST WORKFLOW IN COMMUNITYCARE 
PCMH structure and co-visits 
The approach of pharmacist integration in CommUnityCare’s PCMH follows the 
“employed model”. Full-time pharmacists are employed in the clinic setting to provide 
direct clinical pharmacy services according to the collaborative practice agreement.56 The 
availability of in-house pharmacists at any time fosters teamwork with physicians and 
other health care professionals.106 This employed model is usually practical for large 
group practices or integrated models of care that can afford to hire staff pharmacists.174 
Being imbedded within the clinic also enables pharmacists convenient access to the 
medical records, which promotes continuity of care.23,116 CommUnityCare PCMHs 
employ the “co-visit model” where recommendations and modifications are shared with 
the referring provider on the same day as the patient’s physician visit. This same day 
consult model has also been employed by other PCMHs, although the consultation may 
be provided by a pharmacist or nurse practitioner in some practices.107,108 During non co-
visit days when pharmacist-only visits are scheduled, care plans are documented between 
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primary care appointments. The main difference between the PCMH group and usual 
care group in this study is the availability of co-visits in the PCMH group as opposed to 
only pharmacist-only visits in the usual care group. Allowing trained pharmacists to 
optimize drug therapy and provide patient education at the time of a physician visit 
promotes continuity of care. This may essentially empower the patients and lead to 
increased adherence, improved self-management skills, and attainment of goals.146  
 
Health care professionals involved in PCMH 
The variations in the number of staff in the study clinics are unique to each 
clinic’s needs and patient load. Similar to this study, authors described Pennsylvania 
settings with unique and varied teams of physicians, medical assistants, nurses, nurse 
practitioners, and office managers in most settings and practice managers, patient 
information coordinators, and phlebotomists in select settings.175 Other literature has 
supported inclusion of behavioral health providers (e.g. psychologists, psychiatrists, 
social workers, Master’s -evel therapists, marriage and family counselors) in PCMHs and 
other integrated collaborative care settings.176,177 The need to address mental and 
behavioral health among primary care patients is particularly important for the 
underserved population in this study, and is consistent with the emphasis of whole 
person orientation, coordination and continuity of care of PCMH.177 The VA has also 
reported the inclusion of behavioral health providers in their model of integrated care.178 
 
Workflow and interprofessional collaborations 
According to Smith et al., pharmacist collaboration levels in the present study’s 
PCMH clinics can be categorized as “full collaboration.” In this type of collaboration: 
pharmacists’ roles are well defined within the primary care practice workflow; 
practitioners routinely refer patients to pharmacists; and pharmacists have established 
collaborative drug therapy management agreements. The usual care clinic (UC), on the 
other hand, can be categorized as “partial collaboration.” In this setting, the pharmacists: 
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manage medications between physician visits, incorporate clinical pharmacy services in 
daily huddles; and document patient encounters in the EMRs.  
 
The study sites’ organizational structure adheres to the PCMH principle of 
personal physician and physician-directed medical practice.21 Physicians maintain 
routine physician appointments with patients while pharmacists provide additional 
consultations.  Furthermore, physicians lead the team of medical professionals in the 
FQHCs. Also, the collaborative practice agreement states that each patient should have an 
ongoing relationship with a primary care physician, who is responsible for delegation and 
supervision of drug therapy management provided by pharmacists. Despite the same 
collaborative practice agreement and basic structure of PCMH, implementation of 
pharmacy services differs slightly among the study sites. The provision of integrated 
clinical pharmacy services, for example, conducting co-visits before or after the 
physician appointment, depends on the agreement between the pharmacist and physician, 
as well as the needs of the specific clinic. Similar to another qualitative study,175 
pharmacists in the present study emphasized the importance of being flexible, which 
facilitates physicians’ workflow and allows for more seamless collaboration. Pharmacists 
noted that most co-visit patients are seen prior to their physician visits. This, together 
with pharmacist-only visits, which typically occurs between physician visits, allow 
pharmacists to review patients’ charts prior to making recommendations to physicians.174 
 
Referral and screening of diabetes patients 
The clinics do not have strict referral guidelines. As mentioned previously, 
referral criteria can include a wide range of patients from those with controlled and 
uncontrolled diabetes. According to two studies, targeted referrals based on 
predetermined criteria are more efficient as patients who are more severe can be managed 
more efficiently.24,61 Nonetheless, the less stringent approach in the study clinics provide 
enhanced access for patients. It allows for more patients to benefit from pharmacy 
services, including patients who have clinically controlled diabetes but who may need 
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additional education on self-management strategies. Pharmacists in two of the PCMH 
sites (PCMH1 & PCMH2) proactively screen the physicians’ daily schedules to 
determine which patients may benefit from pharmacy services. Identification of post-
discharge patients or those who need therapy reflects the patient-centeredness, team 
coordination and quality and safety components of the PCMH model. Patients 
identified through referrals and screenings during co-visits are more easily recruited for 
further interventions, as compared to referrals for pharmacist appointments on separate 
days as it can avoid “no-shows” in the latter.  
 
Implementation of clinical pharmacist services 
The number of patient visits per half-day clinic reported in this study is similar to 
that of another PCMH study, where a maximum of 6 patients were seen per session.35 The 
frequency and duration of the visits are dependent on the complexity of the individual 
patient.174 Continuity of care is provided by follow-up visits, which are usually between 
2 weeks to 3 months, with the duration of each visit usually not exceeding 30 minutes. 
This is similar to another study where follow-up appointments occurred every 2 to 6 
weeks with appointment duration of 20 to 30 minutes.107 The same study also mentioned 
that maintenance appointments for patients who reached goals were scheduled every 3 to 
6 months, to prevent “slips” in behavior,107 as opposed to the current study where patients 
are scheduled on an ‘as needed’ basis. Some studies reported longer duration of visits 
with the pharmacist. For example, a study recorded that the average time spent by a 
diabetes disease management team led by a clinical pharmacist was about 39 minutes per 
patient per month, with patient intervention via phone or in person every 2 to 4 weeks.179 
Compared to a PCMH model in Michigan which billed for pharmacist services in 15-
minute blocks (telephone visits) and 30-minute blocks (telephone and face-to-face 





Documentation and communication 
The literature has repeatedly emphasized the importance of communication and 
efficient utilization of the EMR to facilitate team work and coordination.48,65 The physical 
presence of the pharmacists with the prescribing physician on co-visit days facilitates 
communication and enhances interaction between health care providers. Pharmacists 
reported good rapport with the physicians in all clinics. Pharmacists indicated that 
physicians routinely accept their recommendations, which suggests a trusting relationship 
between pharmacists and providers. This effective communication with physicians and 
other health care providers either in person or electronically reflects coordination and 
integrated care in the clinics. 
 
Smith et al. indicated that initial patient visits should be face-to-face to build 
trusted patient-provider relationships, while subsequent follow-up visits can be conducted 
through a combination of face-to-face visits, telephonic and electronic consultations. In 
the study sites, all co-visits and most pharmacist visits are conducted in person with the 
patients and with intermittent telephone calls to follow-up on unique cases. This trend of 
higher face-to-face visits is similar to a PCMH study with 70% of face-to-face visits.35  
4.4 ROLES OF PHARMACISTS ACCORDING TO COLLABORATIVE PRACTICE 
AGREEMENT  
Collaborative practice agreements create a formal practice relationship between 
pharmacists and other providers, defining the range of services that can be provided by 
pharmacists. Similar to what is implemented in the study clinics, these services often 
incorporate MTM provision and collaborative drug therapy management, including 
initiation and modification of drug therapy, ordering and interpretation of laboratory 
results, as well as physical assessment of the patients.180 The extensive provision of 
services by the pharmacists highlights the whole person orientation and patient-
centeredness as emphasized by the Joint Principles of PCMH. 
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Currently, at least 46 states have collaborative practice acts.23 Statutes of 
collaborative practice agreement vary between states and institutions, with at least 36 
states authorizing physician-pharmacist collaborative drug therapy management in any 
setting.181,182 In the state of Texas, pharmacists are authorized to modify drug therapy and 
have prescriptive authority only in specified health facility settings.182 In this study, 
although other health care practitioners (e.g. medical assistant, nurse practitioner) may 
refer patients to the pharmacists, collaborative drug therapy management is authorized 
only for patients referred by primary care physicians. This again, abides by the principles 
of personal physician and physician directed medical practice.  
 
Other studies have a similar framework and literature on such collaborations is 
growing.146,183–185 To illustrate, one interdisciplinary study allowed the clinical pharmacist 
to initiate, adjust, or discontinue pharmacotherapy and order pertinent laboratory tests 
and podiatry referrals that are within the scope of the medication management protocol.185 
The agreement of another collaborative practice model for an outpatient cardiovascular 
pharmacotherapy service however, stated that the roles of pharmacists are to supplement 
physicians in management of the disease. Therefore, in their model, pharmacists provide 
recommendations to physicians instead of independent prescribing.186 
4.5 STRENGTHS AND LIMITATIONS OF CURRENT STRUCTURE 
Strengths  
Same day access to multiple health care providers provides more opportunities for 
direct patient-pharmacist-physician interaction and therefore enhances communication. 
This is viewed as a major advantage as compared to usual care clinics where patients 
referrals to pharmacists occur during a separate visit. This gap in time may lead to 
delayed physician response when issues arise.65,52 Equally important, the open schedule 
arrangement implemented by CommUnityCare clinics is congruent with the enhanced 
access component of PCMH. This arrangement allows for care to be provided for more 
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patients who need pharmacist services, including those who may have missed their 
pharmacist visit if they needed to return to the clinic on a separate day and time.  
 
Pharmacists are well trained in chronic disease management and therefore may be 
one solution to the current shortage of primary care providers in Texas as well as other 
states.182 Successively, through the collaborative practice agreement in PCMHs, more 
integrated services can be provided to diabetes patients, which may improve access to 
care, which is especially important for underserved communities.29,146 Moreover, 
physicians can have more time for additional patient visits when pharmacists manage 
complicated patients with complex drug regimens.174 Such delegation and collaboration is 
aimed to ultimately reduce utilization of more expensive health care resources such as 
specialty care and hospitalizations.29 New models of care for more team based 
management and the complementary skills of pharmacists place them in a unique position 
that is increasingly valued. 
 
Limitations  
One weakness of the open schedule system in the study PCMH clinics, is that 
pharmacists have little control over the types of patients who are on the physician’s 
schedule, which occasionally results in no or few co-visits on designated co-visit days. 
Measures to have diabetes patients on the physician schedule have been discussed with 
the nurse in charge of one of the clinics to resolve this issue. Likewise, missed pharmacist 
appointments can be avoided by having support staff send reminders or call patients prior 
to the pharmacist visit.24 
 
Similar to another study, the most recognizable limitation of the current structure 
is the lack of reimbursement for clinical pharmacy services.107 Payment that recognizes 
the value of a PCMH is one principle of PCMH that is not fully implemented in the study 
sites. Pharmacists currently do not bill for their services, although one pharmacist 
indicated that their clinic plans to do so in the near future. Reimbursement plans for 
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pharmacist-provided services should be developed, and provider status for pharmacists 
should be established to fully maximize pharmacists’ potential to improve the quality of 
patient care.174,182  
 
Apart from the need for more efficient scheduling system and payment 
restructuring to improve the current structure, the number of staff such as pharmacists, 
dietitians and social workers can be optimized to improve interprofessional collaborations 
in the study clinics. Despite these limitations, the current structure and efforts provide a 
framework for future implementation of PCMHs. Co-visits may be expanded to other 
CommUnityCare clinics to improve collaborations and communication between 
healthcare providers and to improve patient care. On a more general scale, legislative 
changes for payment restructuring as well as provision of provider status for pharmacists 
are integral for the further expansion of pharmacists embedment in other PCMHs. 
Table 3.2 Summary of pharmacist implementation of the Joint Principles of PCMH 
Joint 
Principles21 
Description21 Implementation involving 




Each patient has an ongoing 
relationship with a personal physician 
trained to provide first contact, 
continuous and comprehensive care. 
The patients have routine physician 
appointments while the pharmacists 





The personal physician leads a team of 
individuals at the practice level who 
collectively take responsibility for the 
ongoing care of patients. 
Physician leads the team of medical 
professionals. Primary care physician is 
responsible for the delegation and 
supervision of drug therapy 





The personal physician is responsible 
for providing for all the patient’s health 
care needs or taking responsibility for 
appropriately arranging care with other 
qualified professionals. 
Pharmacy services incorporate provision 
of MTM (such as medication 
reconciliation, adherence assessment 
and goal setting) and collaborative drug 
therapy management (authorization to 
prescribe and/or titrate medications, 
order and interpret laboratory results, 
order and administer vaccinations, 
provide disease state education, perform 
physical assessments, document 
interventions, and make referrals to 
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other healthcare team).  





Care is provided across all elements of 
the complex health care system and the 
patient’s community. Care is facilitated 
by registries, information technology, 
health information exchange, and other 
means to assure that patients get the 
indicated care when and where they 
need and want it in a culturally and 
linguistically appropriate manner. 
Pharmacists proactively screen for 
patients who may benefit from 
pharmacy services. Pharmacists actively 
communicate and make referrals to 
physicians and other health care 





Achieved through patient-centered 
partnerships, evidence-based medicine, 
accountability, patients’ participation in 
decision-making, optimal use of 
information technology, and quality 
recognition process. 
Patients are systematically managed 
according to evidence-based medicine 
and are involved in decision-making 





Care is available through systems such 
as open scheduling, expanded hours 
and new options for communication 
between patients, their personal 
physician, and practice staff. 
Flexible referral criteria and open 
scheduling allow for more patients that 
need additional education and pharmacy 
services. 
7. Payment Appropriately recognizes the added 
value provided to patients who have a 
patient-centered medical home. 
The study sites currently lack of 
reimbursement for clinical pharmacy 
services. Arrangements for MTM 
reimbursement are in progress. 
Reimbursement plans and provider 
status for pharmacists should be 
established to fully maximize 
pharmacists’ potential in improving the 
quality of patient care. 
 
  
Table 3.2 continued 
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4.6 STUDY LIMITATIONS  
This study has several limitations. First, the qualitative content analysis of the 
pharmacist interviews may be biased or misrepresented because of researchers’ 
interpretation of pharmacist responses. Second, PCMH implementation varies across sites 
and may limit the generalizability of the results. The generalizability of the results may 
be limited to non-FQHCs, patient populations that are not underserved, and practice 
settings with different collaborative practice agreements or physician-pharmacist 
relationships. Third, we used a small sample size of four participants in this study that 
may not represent all FQHCs in Travis County. Nevertheless, the consistency in the 
responses provided by the participating pharmacists indicate that clinical pharmacist 
services implementation are similar in the PCMH clinics. 
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4.7 CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE RESEARCH  
The structure of PCMH and the integration of pharmacy services employed by 
CommUnityCare incorporated the criteria of the Joint Principles of PCMH, namely: 
personal physician, physician directed medical practice, whole person orientation, care 
coordination and/or integration, quality and safety, and enhanced access. Efforts are 
underway to implement a payment structure for pharmacists. PCMH pharmacists in 
FQHCs were integrated into the workflow to address specific patient needs. Pharmacist 
and physician visits occurring concurrently (i.e. co-visits) helped to facilitate 
communication and collaboration when providing care for patients in underserved 
communities. Strategies for reimbursement are needed to sustain this model of care. 
 
Future research may describe the implementation of PCMH from the perspective 
of other healthcare professionals, such as physicians and nurses, as well as patients. A 
qualitative research via a focus group involving other stakeholders other than pharmacists 
may be useful to explore the interprofessional relationships to improve PCMH structures. 
Objective outcomes such as clinical, utilization and economic outcomes should also be 
investigated to determine the effectiveness of pharmacist-integrated PCMHs. Results 
from quantitative analyses may be used to further evaluate the impact of the PCMH 
structure in FQHCs and serve as models for future development of ACOs and PCMHs 




Appendix A: Semi-structured Interview Guide 
 
Patient-Centered Medical Home (PCMH) Pharmacists  
 
 
1. How is the PCMH structured in your facility? 
a. Who are the staff involved?  
i. How many physicians, pharmacists, pharmacy technicians, nurses, 
case managers are involved? 
b. Describe the interprofessional collaborations.  
i. How do the different health care professionals communicate and 
collaborate regarding the patients’ care? 
ii. How is health information technology (e.g., electronic medical 
record) utilized to facilitate collaborations? 
2. How are patients selected for clinical pharmacy services?  
a. Describe the referral/screening criteria?  
b. Is there a patient registry? 
c. How many patients are referred/identified per week/month? 
d. Once patients who achieve their therapeutic goals, how are they 
continuously monitored?  
i. Are they discharged from follow-up with the clinical pharmacist? 
ii. Are they then followed by their primary care physician?  
iii. Is the follow-up period less frequent? 
3. What services do the clinical pharmacists provide? 
a. Will you please share a copy of your collaborative practice agreement? 
b. Please describe to what extent the following services are provided: 
i. Medication reconciliation, initiation, dosage adjustment via 
collaborative agreement 
ii. Adherence assessment 
iii. Self-management and goal setting 
iv. Patient education on medical condition, nonpharmacologic 
treatment 
v. Order of laboratory tests 
vi. Referral to others e.g. nutritionist, ophthalmologist, local charities 
4. When, specifically, do pharmacists provide clinical services? 
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a. Are patients seen before, after or during the physician visits? Or is the visit 
scheduled independently of the physician visit? 
b. On average, how much time is spent per patient on new and follow-up 
visits? 
c. Regarding follow-up visits - What is the usual planned frequency? 
d. Do you use other methods to provide services besides face-to-face 
sessions? E.g. telephone, email? 
e. Describe the differences in the services provided during a physician co-
visit vs. a pharmacy visit? 
f. Are tests results reviewed during the co-visit or pharmacy visit? Do you 
provide point-of-service testing? 
5. How do you document and communicate the progress notes? Manual, EMR 
a. How do you communicate with the physician(s)? E.g. EMR, telephone, 
face-to-face? 
b. How many recommendations/interventions do you perform a day? e.g. 
dose adjustment, medication change.  What is the overall acceptance rate 
from physicians? 
6. Tell me about your experience working in a PCMH setting. 
a. How long have you been working with this facility and providing MTM in 
this integrated structure? 
b. On average, how many days in a week do you see patients for co-visits 
and pharmacy visits? And how many patients per day? 
c. Do you provide the services outside of clinic hours? E.g. on weekends, 
holidays, after clinic hours? 
d. What are the most common problems encountered by diabetes patients? 
E.g adherence, poor glucose control? 
7. What do you view as the benefits/barriers of the current PCMH model? 
a. Patients 
b. Physicians 
c. Other healthcare providers 
8. What suggestions do you have to improve the PCMH model? 
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Usual Care Pharmacists  
 
 
1. How do healthcare professionals collaborate in your facility? 
a. Who are the staff involved?  
i. How many physicians, pharmacists, pharmacy technicians, nurses, 
case managers are involved? 
b. Describe the interprofessional collaborations.  
i. How do the different health care professionals communicate and 
collaborate regarding the patients’ care? 
ii. How is health information technology (e.g., electronic medical 
record) utilized to facilitate collaborations? 
2. How are patients selected for clinical pharmacy services?  
a. Describe the referral/screening criteria?  
b. Is there a patient registry? 
c. How many patients are referred/identified per week/month? 
d. Once patients who achieve their therapeutic goals, how are they 
continuously monitored?  
i. Are they discharged from follow-up with the clinical pharmacist? 
ii. Are they then followed by their primary care physician?  
iii. Is the follow-up period less frequent? 
3. What services do the clinical pharmacists provide? 
a. Will you please share a copy of your collaborative practice agreement? 
b. Please describe to what extent the following services are provided: 
i. Medication reconciliation, initiation, dosage adjustment via 
collaborative agreement 
ii. Adherence assessment 
iii. Self-management and goal setting 
iv. Patient education on medical condition, nonpharmacologic 
treatment 
v. Order of laboratory tests 
vi. Referral to others e.g. nutritionist, ophthalmologist, local charities 
4. When, specifically, do pharmacists provide clinical services? 
a. Are patients seen before, after or during the physician visits? Or is the visit 
scheduled independently of the physician visit? 
b. On average, how much time is spent per patient on new and follow-up 
visits? 
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c. Regarding follow-up visits - What is the usual planned frequency? 
d. Do you use other methods to provide services besides face-to-face 
sessions? E.g. telephone, email? 
e. Describe the differences in the services provided during a physician co-
visit vs. a pharmacy visit? 
f. Are tests results reviewed during the co-visit or pharmacy visit? Do you 
provide point-of-service testing? 
5. How do you document and communicate the progress notes? Manual, EMR 
a. How do you communicate with the physician(s)? E.g. EMR, telephone, 
face-to-face? 
b. How many recommendations/interventions do you perform a day? e.g. 
dose adjustment, medication change.  What is the overall acceptance rate 
from physicians? 
6. Tell me about your experience working as a clinical pharmacist. 
a. How long have you been working with this facility and providing MTM? 
b. On average, how many days in a week do you see patients for co-visits 
and pharmacy visits? And how many patients per day? 
c. Do you provide the services outside of clinic hours? E.g. on weekends, 
holidays, after clinic hours? 
d. What are the most common problems encountered by diabetes patients? 
E.g adherence, poor glucose control? 




c. Other healthcare providers 
8. What suggestions do you have to improve the current structure? 
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